

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 April 2002 (25.04.2002)

PCT

(10) International Publication Number
WO 02/32940 A2

- (51) International Patent Classification⁷: **C07K 14/00**
- (21) International Application Number: PCT/US01/32457
- (22) International Filing Date: 18 October 2001 (18.10.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/241,248 18 October 2000 (18.10.2000) US
60/327,273 5 October 2001 (05.10.2001) US
- (71) Applicant: **CHILDREN'S MEDICAL CENTER CORPORATION** [US/US]; 300 Longwood Avenue, Boston, MA 02115 (US).
- (72) Inventors: **ASKAR, Samy**; 12 Stoneholm Street, Apartment 606, Boston, MA 02115 (US). **SALCEDO, Jairo**; 400 Brookline Avenue, Apartment 3A, Boston, MA 02115 (US).
- (74) Agents: **PABST, Patrea, L.** et al.; Holland & Knight LLP, One Atlantic Center, Suite 2000, 1201 West Peachtree Street, Atlanta, GA 30309-3400 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
— with sequence listing part of description published separately in electronic form and available upon request from the International Bureau
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: OSTEOPONTIN-COATED SURFACES AND METHODS OF USE

(57) Abstract: An osteopontin containing implant which increases the rate of osseointegration and the percentage of bone apposition is described. In one embodiment, the implant includes osteopontin or an active fragment thereof or an active peptide derived therefrom. In another embodiment, the implant includes a material suitable for use *in vivo* within a subject in combination with a releasable form of osteopontin forming an osteopontin containing implant. The disclosed osteopontin derived peptides bind to various cell types and play important roles in cellular differentiation and/or motility. Many of these interactions are mediated by integrins as disclosed. Antibodies provide a mechanism to abolish or attenuate the activities of the claimed peptides.



WO 02/32940 A2

OSTEOPONTIN-COATED SURFACES AND METHODS OF USE

This application is related to U.S. Provisional Application Nos.
60/241,248 filed on October 18, 2000, and 60/327,273 filed on October 5,
5 2001.

Background of the Invention

The process that leads to successful osseointegration of an implant
into the surrounding tissues is a complex one that involves cell migration,
10 attachment, differentiation, proliferation, extracellular matrix synthesis and
finally mineralization of that matrix. Implant materials are as biocompatible
as their surface chemistry allows for a favorable interaction with the
biological molecules relevant for that tissue.

For example, placement of endosseous dental implants has been
15 limited to areas of favorable bone character, and fixtures must remain
unloaded after placement for considerable periods of time. The primary
challenges faced in the fabrication of new endosseous implants are to
increase the rate of osseointegration and the percentage of bone apposition.
Histological analysis of integrated titanium (Ti) implants into bone tissue
20 revealed that many clinically successful implants are 30 - 60 % apposed
directly by mineralized bone. The rest of the implant surface has been found
to be apposed by fibrous tissue and unmineralized collagen fibers. It is
desirable that the entire circumference of the osseointegrated implant be
directly apposed by mineralized bone tissue.

25 Extracellular matrix proteins, especially certain adhesion molecules,
play a role in bone repair and morphogenesis. These molecules can modulate
gene expression through cell surface-extracellular matrix interactions. The
interaction between the titanium oxide layer of dental implants and certain
extracellular matrix proteins may be a prerequisite for reproducible direct
30 apposition of bone to titanium implants.

The adherence of cells to extracellular matrices (ECM) is a receptor
mediated event leading to the assembly and reorganization of specific
extracellular, transmembrane, and cytosolic components. Integrins represent
a superfamily of cell surface proteins, most of which are composed of
35 heterodimers of an α -subunit and a β -subunit. Examples of receptors and
integrin type receptors are fibronectin and vitronectin receptors of
fibroblasts, IIb/IIIa surface glycoproteins, and those discussed below. Cell

surface receptors belonging to the integrin superfamily are recognized as critical players in the adhesion to the ECM and are intermediate messengers, relaying the recognition signal to cellular events such as *cell* motility, secretion, gene expression, differentiation, and contact or anchorage-dependent growth. Therefore, proteins or compounds that bind to these described receptors may influence a wide range of biological processes.

Osteopontin (OPN) and many peptides derived therefrom are such proteins. While aspartate residues in osteopontin appear to be critical for hydroxyapatite binding, the RGD sequence appears to mediate cell attachment via integrin receptors and thereby activate signal transduction pathways within the cell. Cleavage of osteopontin by thrombin has been reported to enhance the ability of cells to attach and spread *in vitro* (Senger et al., 1994, Mol. Biol. Cell., 5, 565-574), suggesting that thrombin cleavage makes the RGD motif more accessible. OPN has been localized to both bone and cementum and is the only protein detected, thus far, at the interface between bone (or cementum) and implants. Furthermore, osteopontin has also been detected within cementum at the site of insertion of Sharpey's fibers into cementum, suggesting a structural role of the protein in periodontal ligament formation. Sharpey's fibers are collagenous fibers that extend from periodontal ligaments into bone tissue and thereby provide stable connections with teeth, for example. Several laboratories have demonstrated differential attachment of osteoclasts, osteoblasts, macrophages or endothelial cells to surfaces coated with a variety of osteopontins. The "cryptic" nature of osteopontin is also exploited to investigate potential avenues for cell binding and influencing cellular differentiation and migration.

Matrix and Environment Dependent Differentiation

Attachment and proliferation of cells to a provisional matrix does not guarantee that these cells will differentiate into mature cells and express the necessary genes for proper matrix synthesis. When cells initially encounter a bio-matrix or extracellular matrix they will either attach and spread or they will undergo apoptosis. If the cells attach and spread, the cells are faced with two further alternatives, entering into the G1 phase of the cell cycle and proliferate, or up-regulating the expression of certain differentiation genes. Which alternative the cell "chooses" may depend on factors such as local extracellular signals and/or cues, and the type of cell (for example, whether or not the cell is terminally differentiated, precursor, or stem). Increasing

evidence demonstrates that contact with the appropriate extracellular matrix is required to suppress the potential for cells to trans-differentiate. Trans-differentiation is defined as the process whereby a differentiated cell begins to express genes associated with another phenotype; for example, when
5 epithelium cells become mesenchymal.

One of skill in the art will appreciate the complexity of the pathways that lead to committed precursor cells and differentiated cells. Differentiated cells originate from "primitive" cells, called stem cells. Generally, the stem cell is pluripotent and divides to either generate more pluripotent stem cells
10 or committed precursor cells. Committed precursor cells are irreversibly determined to produce only one or a few types of cells. These cells also divide very rapidly but only for a limited number of times. After a series of rapid cell divisions, they develop into differentiated cells, wherein a contribution is made to the surrounding matrix. Driving this process of
15 cellular development is motility (chemotaxis and/or haptotaxis) and/or proliferation, wherein motility and proliferation are regulated by, for example, increasing or decreasing gradients of, for example, peptides, proteins, cytokines, nutrients and/or hormones which bind to receptors on the cell surface.

20 Human osteoblast cell lines undergo a coordinated temporal expression of osteoblast phenotypic markers during their differentiation *in vitro* and produce a mineralized extracellular matrix. This bone developmental system is ideal for studying the interaction between titanium surfaces and bone cells *in vitro*.

25 Peptides that exhibit activity similar to OPN, and novel peptides that interact with many receptors including those, for example, $\alpha_v\beta_3$, $\alpha_v\beta_5$, $4\beta_1$, $2\beta_1$, VCAM, ICAM, CD44, V_3V_x have been identified. These receptors are found on the surfaces of various cell types, including those found on stem, limited potential precursors, precursors, committed precursors, and differentiated
30 cells, and provide internal signals based upon the extracellular cue(s) they recognize. Integrin-type cell receptors mediate the adhesion of the cell to the extracellular surroundings or matrix. These receptors also govern molecular signal transduction events and pathways inside of the cell in response to whatever compound, peptide, protein or extracellular cue it recognizes and
35 binds. Many cell types require anchorage to a matrix to ensure growth and viability and many integrins have provided this link between the extracellular matrix and essential internal cellular activity. Antibodies directed towards

any of the above identified receptors may be used in attenuating or completely abolishing the activity of interacting peptides.

The peptides function in bringing stem cells, precursor cells (committed and uncommitted), and differentiated cells into contact with bone, cementum, PDL matrices or other biomaterials. Obtaining compounds that exert their activity by binding to the receptors, such as $\alpha_v\beta_3$, $\alpha_v\beta_5$, $4\beta_1$, $2\beta_1$, VCAM, ICAM, CD44, V_3V_x , allows one to influence or dictate differentiation process and recruitment. Once recruited to the matrix of interest, cell-cell communication increases the overall effectiveness of the compound.

Cell Attachment and Recruitment in Disease

Eosinophils, which make up one to three percent of the total white blood cell count, have been shown to contribute to a variety of diseases. Chronic allergic diseases such as bronchial asthma, or syndromes such as eosinophilic fasciitis or eosinophilic gastroenteritis are characterized by preferential accumulation of eosinophils at sites in airway inflammation in asthma, infiltration of eosinophils in affected muscle, tissue and fascia, and eosinophilic infiltration of mucosa, submucosa and muscularis of the small bowel, respectively. Eosinophils interact with ligands, the extracellular matrix, endothelial cells and epithelial cells via many of the same cell adhesion receptors and integrins discussed above. These interactions are critical to the infiltration and accumulation of eosinophils. Mechanisms by which one can control the migration process of cells like eosinophils, will be useful in the treatment of debilitating diseases. Integrins and integrin-like receptors therefore play a critical role in the unwanted accumulation of many cell types in human disease.

Summary of the Invention

Molecules and/or compounds involved in directing the migration or the attachment of cells to matrices of a particular environment are of interest in the presently described invention. The implants coated with these peptides increase the rate of osseointegration and the percentage of bone

apposition. Implant surfaces should have such properties which permit the phenomenology of the relevant cells. The achievement of reproducible biological integration of implants calls for a delineation of the molecular biological events relevant to the morphogenesis of the desired interfacial tissue. Material surfaces that can not bind the macromolecules supportive of osteoblast function, are not likely to make a good bone implant. An enhanced rate of osseointegration and/or augmented percentage of bone apposition around implants or cell recruitment systems of the invention increases implant placement indications, expedites loading time, and opens new fields for research in implant materials.

In some embodiments, the implant includes a material suitable for use *in vivo* within a subject in combination with a releasable form of osteopontin forming an osteopontin containing implant.

In another embodiment, the implant includes a material suitable for use *in vivo* within a subject in combination with at least two osteopontin polypeptides forming an osteopontin containing implant.

In yet another embodiment, the implant includes a material suitable for use *in vivo* within a subject in combination with at least two osteopontin active polypeptides, wherein the active polypeptides are attached to the material such that upon implantation into the subject the osteopontin containing implant induces new bone formation.

In another embodiment, the implant includes a material suitable for use *in vivo* within a subject in combination with an osteopontin-derived peptide, wherein the osteopontin-derived peptide is attached to the material such that upon implantation into the subject the osteopontin-derived peptide containing implant induces new bone formation.

In another embodiment, the implant includes a material suitable for use *in vivo* within a subject in combination with a releasable form of osteopontin, wherein the osteopontin is attached to the material such that

upon implantation into the subject the osteopontin containing implant induces new bone formation.

In another aspect the invention features an osteopontin containing titanium implant. The implant includes a releasable form of phosphorylated osteopontin in combination with titanium suitable for use *in vivo* within a subject forming an osteopontin containing titanium implant.

In another aspect the invention features an osteopontin-derived peptide containing titanium implant. The implant includes an osteopontin-derived peptide in combination with titanium suitable for use *in vivo* within a subject forming an osteopontin-derived peptide containing titanium implant.

In yet another aspect the invention features a method of coating an implant with osteopontin, an active fragment thereof, or an osteopontin-derived peptide. The method includes non-covalently or electrostatically attaching osteopontin, an active fragment thereof, or an osteopontin-derived peptide to a surface of an implant, wherein the osteopontin, an active fragment thereof, or an osteopontin-derived peptide is attached to the surface of the implant such that it is releasable from the surface upon implantation into a subject.

The methods are useful in inducing new bone formation in a subject. The method includes implanting an implant, as described above, into a subject, wherein the osteopontin is released from the implant into the subject thereby inducing new bone formation in the subject.

In another embodiment an osteopontin containing cell recruitment system including a releasable osteopontin or a fragment thereof or a peptide derived therefrom in a form which provides a gradient and an implant used to form a cell recruitment system in the proximity of the implant, wherein the implant is targeted for cell recruitment by a gradient of osteopontin which forms in the proximity of the implant.

In another aspect the invention features a coated osseointegrator capable of implantation. The osseointegrator includes a coated material which is enhanced for osseointegration by at least about 100% when

compared to an uncoated material based on the human osteoblast cell (HOS) attachment assay.

In another aspect the invention features a coated implant. The implant includes a coated material which increases the proliferation of osteoblasts by at least about 100% when compared to an uncoated material based on the human osteoblast cell (HOS) proliferation assay.

In still another aspect, the invention features a method for inducing new tissue formation in a subject at a site where tissue formation is needed. The method includes adding osteopontin or a fragment thereof or a peptide derived therefrom into a subject at a site where tissue formation is needed, wherein the osteopontin induces new tissue formation about the site.

In yet another aspect, the invention features an osteopontin glue which includes osteopontin, a mucopolysaccharide and a multivalent metal, e.g., calcium, magnesium or manganese. Preferably, the osteopontin is at a concentration of about 100 µg/g of glue.

In yet another embodiment, the invention features an isolated active osteopontin fragment or an osteopontin-derived fragment, for example, an active osteopontin fragment or an osteopontin-derived fragment having a cell attachment activity or active osteopontin fragment or an osteopontin-derived fragment having chemotactic activity. Preferred active osteopontin fragments and/or osteopontin-derived fragments include but are not limited to fragments or peptides including or having the sequence LVLDPK (SEQ ID NO: 2), or LVVDPK (SEQ ID NO: 3), peptides or fragments including or having the sequence RGRDS (SEQ ID NO: 4), peptides or fragments including or having the sequence X, X', D, Z, Z1, wherein X and X' are hydrophobic amino acids, D is aspartic acid, Z is proline (P), glycine (G), or serine (S), and Z' is a basic amino acid, peptides or fragments including or having the sequence GRGDS (SEQ ID NO: 5), peptides or fragments including or having the sequence VFTPVVPTVDTYDGRGDSVVYGLRSKSKKFRR (SEQ ID NO: 6) or VFTPVVPTVDTYDGRGDSVVYGLRSKSKKFRRP (SEQ ID NO. 7), and

petides or fragments including or having the sequence

RSRRATEVFTPVVPTVDITYDGRGDSVVYGLRSKSKKFRRP (SEQ ID NO:8) (herein referred to as "OC-1016").

In yet another embodiment, the invention features isolated peptide
 5 fragments having a cell attachment activity and/or cell spread activity.
 Preferred peptides include but are not limited to fragments or peptides
 including or having the sequence
 SDELVTDFPTDLPATEVFTPVVPTVDITYDGRGDSVVYGLRSKSKKFRR
 RP (SEQ ID NO:9),
 10 RSRRATEVFTPVVPTVDITYDGRGDSVVYGRRSKSKKFRRP (SEQ ID
 NO:10),
 RSRRATEVFTPVVPTVDITYDGRGDSVVYGRRSKSKKFRRPAGAAGG
 PAGPAG PAGPAGPAGPA (SEQ ID NO:11),
 RSRRVFTPFIPTESANDGRGDSVAYGLKSKSKKFRR (SEQ ID NO:12),
 15 DTFTPIVPTVDVPNGRFDSLAYGLKSKSKKFQ (SEQ ID NO:13),
 RSRRATEVFTPVVPTVDITYDGRADSVVYGRRSKSKKFRRP (SEQ ID
 NO:14), or acetyl-
 RSRRATEVFTPVVPTVDITYDGRGDSVVYGLRSKSKKFRRP (SEQ ID
 NO:15) (herein referred to as "modified OC-1016" or "mOC-1016").

20 The invention also pertains to peptides and osteopontin derived
 peptides and their regulatory activities pertaining to cellular spreading,
 chemotaxis, haptotaxis, and differentiation. Examples of cell types include,
 but are not limited to, osteoprogenitor cells, tumor cells, macrophages,
 periosteal cells, endothelial cells, epithelial cells, eosinophils and more
 25 generally, stem cells, limited potential precursor cells, precursor cells,
 committed precursor cells, and differentiated cells. The peptides, including
 OC-1016 and mOC-1016, are also active as anti-inflammatory agents.

The present invention is directed to isolated peptide molecules, their
 ability to bind to cells and modulate various cellular processes including
 30 differentiation. The present invention also pertains to antibodies, in

particular monoclonal antibodies, which specifically bind to two forms of an osteopontin derived peptide (OC-1016 and mOC-1016, discussed below).

In another aspect, the invention features human osteoblast cell lines in which osteopontin expression is controlled by a constitutive promoter.

5 One of skill will realize that given what is known in the art, osteopontin expression may also be expressed from a regulatable promoter. The regulation of such expression, or constitutive expression, will provide one with ability to modulate cellular processes including cell spreading, chemo- and hapto-taxis and therefore an indirect capability to influence wound
10 healing, immune responses, bone development, tissue remodeling, and metastasis.

In another aspect of the invention, an osteopontin derived peptide is provided that binds to eosinophils. Eosinophil interacting peptides provide one with a mechanism to modulate eosinophil activity and therefore
15 influence binding and recruitment behavior of eosinophils.

In another embodiment, the invention provides peptides that may be used in a method for promoting cell migration or cell differentiation to or in a target site, respectively. A therapeutically effective amount of the peptide(s) such that migration of a desired cell type to a target site is promoted. The
20 peptides may be delivered or injected into the target site.

In yet another aspect of the invention, one may deliver material to a target site or region which is coated with the peptide that binds to cells and promotes their migration.

These examples demonstrate that OC-1016 and mOC-1016 enhance
25 osseointegration *in vivo*, as well as induce cellular proliferation and spread.

Detailed Description of the Drawings

Figure 1 a graph depicting the effect of Ca^{++} ions on the binding of osteopontin to Titanium disks.

Figure 2 is a bar graph depicting the effect of rhOPN on cell
30 attachment to Titanium.

Figure 3 is a bar graph depicting the effect of rhOPN bound to Titanium on cell proliferation.

Figure 4 is a bar graph depicting Apase activity of cells on coated and uncoated Titanium.

5 Figure 5 is a bar graph depicting mineral content of human osteoblast cell culture.

Detailed Description of the Invention

An osteopontin coated implant includes a material suitable for use *in vivo* within a subject in combination with a releasable form of osteopontin forming an osteopontin containing implant.

As used herein, the term "material," refers to a material suitable for use *in vivo* in a subject, e.g., a human or an animal subject, and capable of being part of an implant with osteopontin or a fragment thereof, e.g., releasable osteopontin. There are many art recognized materials suitable for use *in vivo*. These material include, but are not limited to, titanium, tantalum, Vitallium™, glass, plastic, chromocobalt (CrCo), stainless steel, natural or synthetic polymers such as collagen, cellulose, dextran or teflon beads.

As used herein, the term "osteopontin" or "osteopontin polypeptide," refers to a form of osteopontin or a fragment thereof capable of performing its intended function *in vivo*, e.g., a form capable of influencing early bone matrix organization and mineralization through a cell, e.g., osteoblast or osteoclast, attachment. Examples of osteopontin forms include a phosphorylated osteopontin, e.g., an osteopontin having about 6 to about 12 phosphates per mol of protein, preferably, an osteopontin phosphorylated at one or more of the following amino acids selected from the group consisting of Ser26, Ser27, Ser63, Ser76, Ser78, Ser81, Ser99, Ser102, Ser105, Ser108, Ser117, and, preferably Thr138, and most preferably Thr152, a recombinant osteopontin, e.g., a human or murine recombinant osteopontin, e.g., the osteopontin secreted from murine B3H cells, and a naturally occurring osteopontin, e.g., the naturally occurring human osteopontin secreted from

human osteoblast cells (SEQ ID NO: 1). In a preferred embodiment threonine 152 is phosphorylated. In a more preferred embodiment, Ser26, Ser27, Ser81, Thr152 and Ser308 are phosphorylated.

As used herein, the term "active osteopontin peptide" refers to an
 5 osteopontin fragment that possesses at least one biological activity of a naturally occurring osteopontin. Preferred peptides include, but are not limited to, peptides having a chemotactic activity referred to herein as chemotactic peptides, e.g., peptides which comprise the amino acid sequence LVLDPK (SEQ ID NO: 2), or LVVDPK (SEQ ID NO: 3), or having a cell
 10 attachment activity referred to herein as cell attachment peptides, e.g., peptides which comprise the amino acid sequence RGRDS (SEQ ID NO: 4). In preferred embodiments, the osteopontin peptides can be coated onto the material via covalent, non-covalent, or electrostatic interactions.

In an exemplary embodiment, a chemotactic peptide can be a peptide
 15 which comprises an amino acid sequence X, X', D, Z, Z', wherein X and X' are hydrophobic amino acids, D is aspartic acid, Z is proline (P), glycine (G), or serine (S), and Z' is a basic amino acid.

Preferred hydrophobic amino acids include asparagine (N), leucine (L), valine (V), isoleucine (I), glutamine (Q), or methionine (M). Preferred
 20 basic amino acid residues include lysine (K) and arginine (R). In one embodiment X and X' are selected from the group consisting of L, V, I, Q, M; Z is P, G, or S; and Z' is either K or R. In a most preferred embodiment X is L, X' is L, Z is G, and Z' is K.

In another embodiment, a cell attachment peptide comprises the
 25 sequence GRGDS (SEQ ID NO: 5). GRGDS is a cell-binding domain which enhances cell attachment. In another embodiment, a cell attachment peptide has the sequence GRGDS (SEQ ID NO: 5). Preferred active peptides comprise the amino acid sequence
 VFTPVVPTVD TYDGRGDSVVYGLRSKSKKFRR (SEQ ID NO: 6);
 30 VFTPVVPTVD TYDGRGDSVVYGLRSKSKKFRRP (SEQ ID NO: 7);
 SDELVTDFPTDLPATEVFTPVVPTVD TYDGRGDSVVYGLRSKSKKFR

RP (SEQ ID NO: 9);
 RSRRATEVFTPVVPTVDTYDGRGDSVVYGRRSKSKKFRRP (SEQ ID
 NO:10);
 RSRRATEVFTPVVPTVDTYDGRGDSVVYGRRSKSKKFRRPAGAAGG
 5 PAGPAG PAGPAGPAGPA (SEQ ID NO:11);
 RSRRVFTPFIPTESANDGRGDSVAYGLKSKSKKFRR (SEQ ID NO:12);
 and acetyl-RSRRATEVFTPVVPTVDTYDGRGDSVVYGLRSKSKKFRRP
 (SEQ ID NO:15) (m-OC-1016).

In another embodiment, a preferred active peptide does not have an
 10 "RGD" sequence. For example, a preferred active peptide has the amino acid
 sequence DTFTPIVPTVDVPNGRFDLAYGLKSKSKKFQ (SEQ ID
 NO:13). Yet another preferred active peptide has the amino acid sequence
 RSRRATEVFTPVVPTVDTYDGRADSVVYGRRSKSKKFRRP (SEQ ID
 NO:14).

15 As used herein, an osteopontin-derived peptide includes an "active
 osteopontin peptide" as defined herein, including about one, two, three, four,
 five, six, seven, eight, nine or ten residues which differ from the amino acid
 residues present in a naturally occurring active osteopontin peptide, the
 residues not interfering with the activity of the active peptide. For example,
 20 residues can be added at the C- or N-terminus of an active osteopontin
 peptide (*e.g.*, to facilitate purification of the active peptide). Alternatively, a
 relatively few number of residues can be substituted within the consecutive
 sequence of the active peptide (*e.g.*, substituted within the sequence of a
 naturally-occurring osteopontin sequence), the substitutions not interfering
 25 with the activity of the active peptide. A preferred osteopontin-derived
 peptide comprises the amino acid sequence
 RSRRATEVFTPVVPTVDTYDGRGDSVVYGLRSKSKKFRRP (SEQ ID
 NO: 8). Alternatively, any type of chemical modification may be
 incorporated into or attached to any of the peptides. The chemical
 30 modification of choice will not interfere with the activity of the peptide.
 SEQ ID NO:15 (mOC-1016) represents one such example.

As used herein, the phrase "in a releasable form," is intended to include osteopontin coated on top of the material in such a way that an osteopontin or a fragment thereof or a peptide derived therefrom is capable of being released from the surface of the implant and performing its intended function *in vivo*, e.g., it is capable of establishing an osteopontin gradient in the proximity of an implant, preferably, within about 24 hours, more preferably within about 48 hours, of implantation. As used herein, "osteopontin gradient," refers to a protein gradient which results in the recruitment of cells, e.g., osteoblasts or osteoclasts, to an implant. Preferably, the osteopontin is non-covalently or electrostatically attached to the material. Non-covalent attachment is known in the art and includes, but is not limited to, attachment via a divalent ion bridge, e.g., a Ca^{++} , Mg^{++} or Mn^{++} bridge; attachment via absorption of osteopontin or a fragment thereof or a peptide derived therefrom to the material; attachment via plasma spraying or coat drying of a polyamine, e.g., polylysine, polyarginine, spermine, spermidine or cadaverin, onto the material; attachment via a second polypeptide, e.g., fibronectin or collagen, coated onto the material; or attachment via a bifunctional crosslinker, e.g., N-Hydroxysulfosuccinimidyl-4-azidosalicylic acid (Sulfo-NHS-ASA), Sulfosuccinimidyl(4-azidosalicylamido)hexanoate (Sulfo-NHS-LC-ASA), N- γ -maleimidobutyryloxysuccinimide ester (GMBS), N- γ -maleimidobutyryloxysulfosuccinimide ester (Sulfo-GMBS), 4-Succinimidylloxycarbonyl- α -methyl- α -(2-pyridyldithio)-toluene (SMPT), Sulfosuccinimidyl 6[α -methyl- α -(2-pyridyldithio)toluamido]hexanoate (Sulfo-LC-SMPT), N-Succinimidyl-3-(2-pyridyldithio)propionate (SPDP), Succinimidyl 6[3-(2-pyridyldithio)propionamido]hexanoate (LC-SPDP), Sulfosuccinimidyl 6-[3-(2-pyridyldithio)propionamido]hexanoate (Sulfo-LC-SPDP), Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), Sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (Sulfo-SMCC), m-Maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), m-Maleimidobenzoyl-N-hydroxysulfosuccinimide ester (Sulfo MBS), N-Succinimidyl(4-iodoacetyl)amino benzoate (SIAB),

Sulfosuccinimidyl(4-iodoacetyl)amino benzoate (Sulfo-SIAB), Succinimidyl 4-(ρ -maleimidophenyl) butyrate (SMPB), Sulfosuccinimidyl 4(ρ -maleimidophenyl) butyrate (Sulfo-SMPB), or Azidobenzoyl hydrazide (ABH), to the material. In other preferred embodiments osteopontin or a
5 fragment thereof or a peptide derived therefrom is attached to the material via an electrostatic interaction.

Alternatively, the osteopontin can be attached to an implant for tissue surface via non-covalent attachment, as described above, further including a mucopolysaccharide. Mucopolysaccharides are art recognized and include
10 glycosaminoglycans having, for example, repeating units of N-acetylchondrosine or β 1-3 glucuronidic and β 1-4 gluconsaminidic groups. Suitable mucopolysaccharides include chondroitin sulfate or hyaluronic acid. Preferably, hyaluronic acid is greater than a disaccharide; the hyaluronic acid has a molecular weight range of less than 100 kDa, more preferably between
15 about 20 to about 100 kDa, e.g. between about 50-100, 70-100, or 30-80 kDa.

As used herein, the term "implant," refers to a surgical implant suitable for use *in vivo* and where it would be desirable to have osteopontin for promoting cell, e.g., osteoblast or osteoclast, attachment. Examples of
20 suitable implants include but are not limited to dental implants, e.g., dental screws or fixtures, jaw modification implants, face reconstruction implants, orthopedic implants, e.g., orthopedic screws, rods or joints, e.g., hip or knee replacement implants. A preferred implant is a titanium dental implant.

As used herein, the phrase "an osteopontin containing cell
25 recruitment system" refers to a system in which osteopontin or a fragment thereof or a peptide derived therefrom is introduced into a subject independent of an implant. Preferably, the osteopontin or a fragment thereof or a peptide derived therefrom is introduced in the proximity of an implant in a form of a gel or a sponge. In other preferred embodiments, the osteopontin
30 or a fragment thereof or a peptide derived therefrom contained in a gel or a sponge is capable of generating a gradient of osteopontin in the proximity of

an implant such that cells, e.g., osteoblasts or osteoclasts, are recruited to the implant. The phrase "an osteopontin containing cell recruitment system" is also intended to include chemotactic effects of osteopontin in facilitating wound healing and stimulating the recruitment of tissue remodeling cells from surrounding tissues. Tissue remodeling cells include mesenchymal, macrophage and granulocytes. Wound healing cells include, for example, cytokines which include TGFB and growth factors, cell-stimulating molecules and healing cells such as macrophages which help to clear chronic necrotic tissue from damaged tissue area.

The term "mesenchymal cell" is art recognized and is intended to include undifferentiated cells found in mesenchymal tissue, e.g., undifferentiated tissue composed of branching cells embedded in a fluid matrix which is responsible for the production of connective tissue, blood vessels, blood, lymphatic system and differentiates into various specialized connective tissues.

The term "growth factors" is art recognized and is intended to include, but is not limited to, one or more of platelet derived growth factors (PDGF), e.g., PDGF AA, PDGF BB; insulin-like growth factors (IGF), e.g., IGF-I, IGF-II; fibroblast growth factors (FGF), e.g., acidic FGF, basic FGF, β -endothelial cell growth factor, FGF 4, FGF 5, FGF 6, FGF 7, FGF 8, and FGF 9; transforming growth factors (TGF), e.g., TGF- β 1, TGF- β 1.2, TGF- β 2, TGF- β 3, TGF- β 5; bone morphogenic proteins (BMP), e.g., BMP 1, BMP 2, BMP 3, BMP 4; vascular endothelial growth factors (VEGF), e.g., VEGF, placenta growth factor; epidermal growth factors (EGF), e.g., EGF, amphiregulin, betacellulin, heparin binding EGF; interleukins, e.g., IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14; colony stimulating factors (CSF), e.g., CSF-G, CSF-GM, CSF-M; nerve growth factor (NGF); stem cell factor; hepatocyte growth factor, and ciliary neurotrophic factor. Adams et al., "Regulation of Development and Differentiation by the Extracellular Matrix" *Development* Vol. 117, p. 1183-1198 (1993) (hereinafter "Adams et al.") and Kreis *et al.* editors of the book

entitled "Guidebook to the Extracellular Matrix and Adhesion Proteins,"
Oxford University Press (1993) (hereinafter "Kreis et al.") describe
extracellular matrix components that regulate differentiation and
development. Further, Adams et al. disclose examples of association of
5 growth factors with extracellular matrix proteins and that the extracellular
matrix is an important part of the micro-environment and, in collaboration
with growth factors, plays a central role in regulating differentiation and
development.

As used herein, the phrase "inducing new bone formation," refers to a
10 process which results in attachment, proliferation and/or differentiation of
bone cells, e.g., osteoblasts and/or osteoclasts, and subsequent bone
mineralization, in the proximity of an implant.

As used herein, the phrase "a coated osseointegrator capable of
implantation," refers to a coated material which when implanted into a
15 subject *in vivo* enhances osseointegration in the vicinity of the coated
material by at least about 100% when compared to an uncoated material.
Preferably, the coated material is a material coated with an osteopontin or a
fragment thereof or a peptide derived therefrom, as described herein. In
other preferred embodiments, the rate of osseointegration is enhanced by at
20 least about 300%, 500%, 800%, 1000%, 1100% or 1200%, when compared
to an uncoated material. The percentage values intermediate to those listed
also are intended to be part of this invention, e.g., 350%, 875%, or 1150%.
Rate of osseointegration can be measured using the human osteoblast cell
(HOS) attachment assay as described in Examples 2 and 7 below, or by other
25 methods known to those of skill in the art.

As used herein, the term "coated implant," refers to a coated material
which when implanted into a subject *in vivo* increases the proliferation of
osteoblasts in the vicinity of the coated material by at least about 100% when
compared to an uncoated material. Preferably, the coated material is a
30 material coated with an osteopontin or a fragment thereof or a peptide
derived therefrom, as described herein. In other preferred embodiments, the

rate of proliferation is increased by at least about 50%, more preferably by at least about 200%, when compared to an uncoated material. The percentage values intermediate to those listed also are intended to be part of this invention, e.g., 75%, 125% or 150%. Rate of proliferation can be measured
5 using the human osteoblast cell (HOS) proliferation assay as described in Examples 3 and 8 below, or by other methods known to those of skill in the art.

The present invention is also directed to methods for inducing new tissue formation in a subject at a site where tissue formation is required. The
10 methods include adding osteopontin into a subject at a site where tissue formation is needed, wherein the osteopontin induces new tissue formation about the site. In a preferred embodiment the osteopontin is a recombinant osteopontin. In a most preferred embodiment, the site includes an implant as described herein.

15 A osteopontin glue includes osteopontin, a mucopolysaccharide and a multivalent metal. Suitable multivalent metals include copper, zinc, barium, calcium, magnesium, and manganese. The osteopontin glue can be administered to an area of tissue in need of repair, e.g., a wound, a cut, or other damaged tissue area, e.g., necrotic tissue. The osteopontin glue can be
20 administered by methods known to those skilled in the art, such as, via injection. Administration of the osteopontin glue enhances tissue regeneration with concomitant removal of necrotic cells. In a preferred embodiment, the osteopontin glue can be used with an implant as described herein.

25 They are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Injection or topical application is preferred.

The phrases "parenteral administration" and "administered
30 parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without

limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.

5 Actual dosage levels of the active ingredients in the pharmaceutical compositions may be varied so as to obtain an amount of the active ingredients which are effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

10 The selected dosage level will depend upon a variety of factors including the activity of osteopontin of the present invention employed, the route of administration, the time of administration, the rate of excretion of the osteopontin being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the osteopontin
15 employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts. In a preferred embodiment the concentration of osteopontin in the glue is between about 0.1 μg to about 100 μg , preferably about 100 $\mu\text{g/g}$ of carrier.

20 Not wishing to be bound by theory, it is believed that the osteopontin glue provides a mechanism for "laminating" tissue to tissue or tissue to implant. A plausible explanation for glue's ability to facilitate tissue reconstruction or repair is as follows: Mucopolysaccharides include both hydrophobic and hydrophilic domains, for example, which can coat, e.g.,
25 adhere to, the surface of implant or tissue. The mucopolysaccharide provides ionic charge for a multivalent cation to interact with the mucopolysaccharide, acting as a bridge between the implant surface and osteopontin. Once the osteopontin is within the region where cell-recruitment is required, the osteopontin helps to facilitate the regeneration of the tissue in the gradient
30 area of the osteopontin. Alternatively, an implant surface may be oxidized so that the multivalent metal can bind with the oxidized surface, thus providing

a bridge directly to the osteopontin. It can be envisioned that interactions between the osteopontin and further layers of mucopolysaccharides can further produce a laminating effect for multiple layers of mucopolysaccharide, multivalent metal, osteopontin.

5 The phrase "pharmaceutically acceptable carrier" is art recognized and includes a pharmaceutically acceptable material, composition or carrier, suitable for administering osteopontin compositions of the invention to mammals by injection. The vehicles include liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or
10 transporting the bone precursor composition from a syringe to the cavity in need thereof. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable vehicles, include: sugars, such as lactose,
15 glucose and sucrose; starches such as cornstarch and potato starch; cellulose and its derivatives, such as sodium carboxy methylcellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil;
20 glycol such as propylene glycol; polyols such as glycerin, sorbitol, manitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible
25 substances employed in pharmaceutical formulations.

Wetting agents, emulsifiers and lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, stabilizers, preservatives or antioxidants can also be present in the compositions.

Methods of preparing these formulations or compositions include the
30 step of bringing into association the osteopontin glue compositions of the present invention with a carrier and, optionally, one or more accessory

ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the components of the osteopontin glue of the present invention with the carrier.

Liquid dosage forms suitable for administration of the osteopontin glue compositions of the invention include pharmaceutically acceptable emulsions and microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredients, e.g. osteopontin, multivalent metals and mucopolysaccharides, the liquid dosage form can contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethyleneglycols and fatty acid esters, sorbitan and mixtures thereof.

The osteopontin compositions can also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be insured by the inclusion of various anti-bacterial and anti-fungal agents, for example, paraben, chlorobutanol, and phenol sorbic acid. It may also be desirable to include isotonic agents, sugars, or salts such as sodium chloride. In addition, prolonged absorption of the osteopontin compositions can be brought about by the inclusion of agents which allay absorption such as aluminum monostearate and gelatin e.g., collagen.

In Vitro Modification of Osteopontin

Phosphorylation of osteopontin:

Both natural and recombinant osteopontin can be modified by phosphorylation of the amino acid sequence encoding native osteopontin. The osteopontin can be modified so that phosphorylation is present in the absence of, or with altered glycosylation. The osteopontin can also be modified so that it has less phosphorylation or more phosphorylation than

native forms of osteopontin, or is phosphorylated at sites other than those which are naturally phosphorylated.

Phosphorylation is achieved by incubation of the osteopontin in the presence of either eucaryotic kinases such as casein kinase type II or cAMP-
5 dependent kinases. These kinases can be obtained from cytosolic or microsomal extracts, or in purified or semi-purified form from sources such as Sigma Chemical Co., Inc., or as described in the literature. As described in the example below, at least three different kinase preparations from mouse kidney could be used to phosphorylated osteopontin *in vitro*. These
10 preparations contain a mixture of kinase activities, several of which can phosphorylate the fusion protein. Casein kinase I, casein kinase II and mammary gland casein kinase participate in hierarchical phosphorylation reactions. Phosphorylation of one site by any of these kinases may affect phosphorylation at another site by a different kinase.

15 As further demonstrated by the examples below, osteopontin appears to be a complex substrate with at least 58 consensus phosphorylation sites for different types of kinases, as shown in Table I. These putative phosphorylation sites are not randomly distributed throughout the protein but appear as if they were organized in eight clusters. For example, between
20 residues 100 and 126 there are 9 potential phosphorylation sites for either casein kinase I, casein kinase II or mammary gland casein kinase. In addition to potential phosphorylation sites for these independent casein kinase family of enzymes, osteopontin also contains potential phosphorylation sites for cAMP- and cGMP-dependent protein kinases,
25 calmodulin-dependent protein kinase, and protein kinase c. There are several fold more potential phosphorylation sites in recombinant osteopontin than those found phosphorylated in osteopontin isolated from bone. Not all of the potential sites may be phosphorylated at any given time, since some sites may be not accessible to protein kinases or some tissues may not contain all
30 of the kinase activities required for the phosphorylation of osteopontin. Furthermore, the clustering of sites suggests that certain phosphorylated

residues can serve as specificity determinants. For example, phosphorylation of a Ser/Thr residue by any kinase can generate a site for phosphorylation of an adjacent phosphorylatable residue by either casein kinase I or mammary gland casein kinase. Conversely, phosphorylation at one site by a particular
5 kinase may suppress the phosphorylation of a nearby residue, such as the mutually exclusive phosphorylation of hormone-sensitive lipase by cAMP-dependent protein kinase and calmodulin-dependent protein kinase.

Further modifications on the site and extent of phosphorylation can be achieved by expression of osteopontins with altered structures by
10 differential splicing and post-translational modifications, as well as by the use of fragments and site-specific mutations at any one of these phosphorylation sites.

For phosphorylation by calcium/calmodulin kinase II, the reactions are carried out in the presence of 1.5 mM CaCl_2 and 3 μg calmodulin. For
15 phosphorylation by protein kinase C, the reactions are carried out in the presence of 8 $\mu\text{g/ml}$ phosphatidylserine, 0.8 $\mu\text{g/ml}$ of diacylglycerol, and 1 mM CaCl_2 . For autophosphorylation the reaction is carried out in the presence of 10 mM MnCl_2 . For phosphorylation by cGMP dependent protein kinase the reactions are carried out in the presence of 0.1 μM cGMP.
20 No additions are necessary for the phosphorylation of osteopontin by casein kinase I or mammary gland casein kinase.

Determination of phosphorylation sites in osteopontin:

After phosphorylation with ^{32}P -ATP and the desired kinase, osteopontin is digested with either trypsin, endopeptidase Glu-C, or
25 endopeptidase Asp-N. The resulting peptides are separated by HPLC and the radiolabeled peptides sequenced. The position of the phosphorylated residue is determined by the coelution of radioactivity with the amino acid in that cycle.

Dephosphorylation of Osteopontin:

30 Osteopontin can be dephosphorylated by incubating the protein in either 100 μl 20 mM HEPES buffer, pH 8.5, and 1 unit of alkaline

phosphatase, or 100 μ l 20 mM acetate buffer pH, 5.0 and 1 unit of acid
phosphatase, for several hours. Osteopontin can also be dephosphorylated by
incubating the phosphoprotein with between 0.1 and 1 units of protein
phosphatase 2A at 4°C for 1 h. Osteopontin can be also dephosphorylated by
5 incubating the protein in 0.1 N NaOH for 1 h at 37°C.

Table 1: Predicted phosphorylation sites in Osteopontin

Protein Kinase	Position of phosphorylated residue
Casein Kinase I	239, 275, 280, 308
	26, 76, 78, 99, 102, 105, 108, 117, 120, 123, 126, 129, 234, 308
Casein Kinase II	26, 27, 62, 63, 191, 215, 228, 280, 291
	76, 237
Ca/Calmodulin- dependent	162, 171
Protein Kinase II	
cGMP-Dependent	24, 73, 81, 162, 169,
Protein Kinase	171, 243, 270, 275, 303
cAMP-Dependent	224, 243, 270
Protein Kinase	
Protein Kinase C	49, 239, 171
Tyrosine Kinase	165
Proline-Dependent	147
Protein Kinase	

Glycosylation:**N-glycosylation of osteopontin:**

Osteopontin can be N-glycosylated using colichol-P-P-oligosaccharide and microsomal oligosaccharide transferase. The
5 oligosaccharide side chain can be further processed by using enriched golgi preparations and the appropriate UDP-saccharides.

O-glycosylation of osteopontin:

Osteopontin will be O-glycosylated by incubating the protein with commercially available rabbit reticulocyte lysate, which has been
10 demonstrated by glycosylate nascent proteins *in vitro* (e.g., Starr, S.M. and Hanover, J.A. (1990) J. Biol. Chem. 265:6868-6873). Alternatively osteopontin could be O-glycosylated by using purified UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase and UDP-N-acetylgalactosamine. The resulting O-glycosylated protein could be used to
15 build more complex oligosaccharide side chains, using purified transferases and the appropriate sugar derivatives.

Glycation of osteopontin (nonenzymatic):

Non-enzymatic glycation involves the condensation of any sugar aldehyde or ketone, including phosphorylated derivatives of sugars, with
20 either an α or ϵ amino group, resulting first in the rapid formation of a Schiff base. The Schiff base adduct can subsequently rearrange to the more stable Amadori product. For example, incubation of osteopontin with glucose, for several hours, will result in the formation β -pyranosyl Schiff base adduct, which will rearrange, with time, to the β -furanosyl Amadori product.
25 Alternatively, the β -pyranosyl Schiff base adduct can be reduced at for 1 h at 22°C with 0.1% sodium borohydride to yield 1-deoxy-1-aminosorbitol derivative.

Sialation of osteopontin:

O-glycosylated osteopontin can be modified further by the addition of
30 sialic acid. Briefly, 200 μ g of osteopontin will be incubated with 0.5 milliunits of α 2,3-sialyltransferase in 100 μ l 20 mM HEPES buffer pH, 6.5,

containing varying concentrations of CMP-sialic acid for 1 h at 37°C. N-glycosylated osteopontin can be sialated using α 2,6-sialyltransferase and the conditions described above.

Deglycosylation of naturally occurring osteopontin:

5 Osteopontin, isolated from tissues, can be deglycosylated by the following methods:

Removal of N-linked oligosaccharides:

After treatment of osteopontin with neuraminidase to remove sialic acids, osteopontin is incubated overnight with 0.3 units of N-glycanase
10 (Genzyme, Boston, MA) 100 μ l of 20 mM HEPES buffer, pH 7.5, at 37°C.

Removal of O-linked oligosaccharides:

Asialoosteopontin is incubated for 1 to 6 h with 4 milliunits o-glycanase (Genzyme, Boston, MA) in 100 μ l of 20 mM MOPS buffer, pH 6.0, at 37°C.

15 Removal of oligosaccharides from osteopontin:

Total deglycosylation of osteopontin can be achieved by incubating the protein with 0.1% anhydrous trifluoromethanesulphonic acid (TFMS) for several hours. This treatment removes both O- and N-linked oligosaccharides.

20 **Sulfation of osteopontin:**

Sulfation of osteopontin and its derivatives is accomplished using the procedure described by Varahabhotla, et al. (1988) BBA, 966:287-296, using the enzyme sulfotransferase and 3'-phosphoadenosine-5'-phosphosulfate as the sulfate donor. Osteopontin contains 4 tyrosines. The
25 sulfated proteins are then purified by gel permeation chromatography.

Titanium

1 Titanium Surface Characteristics

Titanium (Ti) reacts immediately with oxygen when exposed to air. In less than a millisecond an oxide layer greater than 10Å is formed, and
30 within a minute the oxide thickness will be of the order of 50 to 100Å (Kasemo B, J. Of Prosth Dent. 49(6):832-837, 1983). Ultrasonic cleaning

and autocleaving involves additional growth of the surface oxide, as well as probable incorporation of OH radicals in the oxide (Kasemo B, J. Of Prosth Dent. 49(6):832-837, 1983). Titanium forms several stable oxides such as TiO_2 , TiO , and Ti_2O_3 , with TiO_2 being the most common one. All oxides
5 have high dielectric constants (higher than for most other metal oxides) in the range of 50 to 120. For these reasons a single stoichiometric oxide is not expected to form on the implant surface. The oxide might be called TiO_x , where x gives the average oxygen content of the oxide. The tissue implant reaction is thus a reaction with TiO_2 at the implant surface and not with the
10 element titanium as such (Kasemo B, J. Of Prosth Dent. 49(6):832-837, 1983).

Titanium dioxide has physical/chemical characteristics that differ from metallic titanium; characteristics which are more closely related to ceramics than to metals (LeGeros RZ and Craig RG, J. Of Bone and Mineral
15 Research 8(2):s583-s593, 1993). TiO is bioinert, Ti is biotolerant (LeGeros RZ and Craig RG, J. Of Bone and Mineral Research 8(2):s583-s593, 1993). Biomaterial composition affects surface chemistry and tissue response. Bioinert materials, which include ceramic oxides (alumina, zirconia) and biotolerant materials (metal alloys and polymers) do not become directly
20 attached to the bone, and consequently, the material bone interface is weaker in tension and shear strengths but not necessarily in compression loading.

It has been established that titanium oxide surfaces bind cations, particularly polyvalent cations (Abe M., Oxides and hydrous oxides of multivalent metals as inorganic ion exchangers, Inorganic Ion Exchange
25 Materials (ed. A. Clearfield) CRC Press, Boca Raton, FL, USA, pp 161-273, 1982). Titanium surfaces have a net negative charge at the pH values encountered in animal tissues, the pK being 4.0. This binding of cations is based on electrostatic interactions between titanium-linked O^- on the implant surface, and cations. The oxide layer is highly polar and attracts water and
30 water-soluble molecules in general (Parsegian VA, J. Of Prosth Dent. 49(6):838-841, 1983).

2 The Bone-Titanium Layer

It is known that osseointegrated implants are characterized by the presence of an organic interfacial layer, containing no collagen fibrils, between the bone and the implant. This intervening layer in osseointegrated implants has been reported to stain with lanthanum and alcian blue and is both
5 hyaluronidase and chondroitinase sensitive, suggesting proteoglycan content (Albrektsson T et al, *Annals of Biomedical Engineering*, 11, 1-27, 1983). The thickness of the glycan layer was found to vary with the biocompatibility of the implant material from 20 to 40 nm for Ti and 30 to 50 nm for zirconia
10 (Albrektsson T, Jacobson M, *J. Prosthet Dent* 57:597-607, 1987). Establishment of this layer is reported to be critical for the success of the implant since it may provide an optimal interface between the dental implant and the newly formed bone (Nanci A et al, *Cells and Materials*, 4(1):1-30,1994).

15 Tissue response to commercially pure Titanium (cp Ti) was examined to characterize the bone implant interface. Lectin cytochemistry was used to detect glycoconjugates and immunocytochemistry for noncollagenous bone and plasma proteins. The composition of the titanium-matrix interface with that of natural bone interfaces such as cement lines and laminae limitantes
20 was compared. The concentration of osteopontin (Opn) and alpha HS-glycoprotein at the bone titanium interface was consistent with the composition of cement lines at matrix-matrix interface and laminae limitantes at various cell-matrix interfaces. Furthermore, the data indicated that the interfacial layer between the bone and the implant is also rich in
25 glycoconjugates containing sacharides such as galactose, a sugar residue found in relatively large proportion in osteopontin.

3 Bone Healing around Ti

The idea of osseointegration arose from studies of bone wound healing. Titanium chambers containing a transillumination system were
30 inserted into the fibulae of rabbits to observe cellular changes during endosteal wound healing. At the completion of the study, retrieval of the

titanium chambers required fracture of bone tissue that was integrated into the chamber surface. This incidental finding became the basis for the use of Titanium in endosseous implant construction (Branemark P-I, Introduction to osseointegration. In Branemark P-I, Zarb Ga, Aiberktsson T (eds)
5 Tissue-Integrated prosthesis. Quintessence Publishing Co, Inc., Chicago, pp 11-76, 1985).

The bone trauma generated by implant placement is followed by clot formation, acute inflammation, recruitment and proliferation of stromal cells and their differentiation into osteogenic lineage cell, followed by filling the
10 defect with bone and finally mineralization of the matrix (O'Neal RB et al., J. Oral Implantol. 18:243-255, 1992). Throughout this process; macromolecules, including cytokines and adhesion molecules, that orchestrate the course of wound healing and osteogenesis, are secreted into the extracellular milieu (O'Neal et al, Biological requirements for material
15 integration(1992). J. Oral Implantol. 18:243-255, 1992). The interaction of some of these macromolecules with the implant surface determines to a measurable extent how well the implant is integrated.

Early postoperative motion which can occur with an unstable device impairs bone regeneration leading instead for fibrous repair, encapsulation
20 and chronic inflammation, which can further contribute to instability and more excessive motion. If the interface is not integrated, large shear displacements occurring across the interface may result in combined corrosion and wear (Galante JO et al., J. Of Orthopaedic Research 9:760-775, 1991).

25 The nature of the implant bone interface is also affected by the surface chemistry and topography of the implant. Since titanium does not induce bone formation, one way of assuring apposition of bone cells to the implant is to design an implant surface that is attractant to these molecules and/or supports osteomorphogenesis.

4 Changes On Macroscopic Characteristics Of Titanium

Steps to maximize integration have addressed the implant: Studies about surface of the implant clearly show that bone cells adhere securely onto Titanium surfaces, and rough-textured (acid) and porous-coated Ti surfaces enhance both the synthesis and mineralization of the extracellular matrix (Bowers KT et al., Int. J. of Oral and Max. Imp. 7(3):302-310, 1992, Groessner-Schreiber B, Tuan RS, J. Of Cell Science 101,209-217, 1992). Electrochemical potentials for porous conditions are relatively similar to those for smooth-surfaced conditions. However, corrosion rates are increased for porous conditions due to the added area per unit volume (Galante JO et al, J. Of Orthopaedic Research. 9:760-775, 1991).

5 Healing Of Bone Using Titanium Coated With Proteins

Recent studies have focused on improving the osseointegration of implants into bone by coating the Ti surfaces of implants with various substances including hydroxyapatite (Klein CP et al., Biomaterials. 15(2): 146-50, 1994; Jansen JA et al., J. Biomedical Materials Res. 25(8):973-89, 1991; Holmes RE, Plast. Reconstr Surg 63:626-636, 1979), fibronectin (Rutherford RB et al., Int. J. Oral and Maxillofacial implants. 7(3):297-301,1992), and bone morphological proteins (BMP's) (Xiang W et al, Journal of Oral and Maxillofacial Surgery. 51(6):647-511, 993). Histological examinations of bone/titanium interface from such studies revealed various degrees of success in improving the osseointegration of Ti implants.

Titanium and Osteopontin

1 Protein Expression During Bone Formation

Morphological and histological studies on bone development categorize a linear sequence of cell differentiation progressing from an osteoprogenitor cell to preosteoblasts, osteoblasts and finally osteocytes and lining cells (Aubin JE et al., Analysis of osteoblast lineage and regulation of differentiation. In "Chemistry and Biology of Mineralized Tissue" (H. Slavkin and P Price, eds), pp 267-276. Excerpta Medica, Amsterdam, 1992). Recently, the morphological and histological studies have been

supplemented with the elucidation of some of the specific proteins secreted by bone cells at specific stages during their development. For example collagen type I is secreted by early and mature osteoblasts but decreases with late osteoblasts and osteocytes. Alkaline phosphatase is expressed by preosteoblasts and is accepted as a marker for osteoblasts. Osteopontin and bone sialoprotein are secreted by early osteoblasts, just prior to the onset of mineralization, but decreases as mineralization proceeds and osteoblasts mature and differentiate into osteocytes. Osteoblastic cells in vitro show an initial peak of Opn mRNA expression at early cultured times, followed by a second mayor peak of expression when the cultures begin to mineralize (Owen TA, J. Cell. Physiol. 143, 420-430, 1990; Strauss GP et al., J. Cell. Biol. 110,1368-1378, 1990). Osteocalcin is secreted by mature osteoblasts after the onset of mineralization. The order of appearance of proteins at bone interfaces, particularly with respect to type I collagen, is important in understanding the events leading to bone formation and turn over, and ultimately osseointegration.

2 Possible Role Of Osteopontin In Bone Formation

Osteopontin is a cell adhesion protein first identified in bone, but now associated with other tissues as well. Osteopontin is a phosphorylated glycoprotein containing an RGD cell-binding sequence. In mineralized tissues, OPN is expressed prior to mineralization and regulated by osteotropic hormones, binds to hydroxyapatite, and enhances osteoclast and osteoblast adhesion. Although the exact function of Opn is yet unknown, possibilities include a role in the recruitment of bone precursor cells to a site of mineralization, and a role in protection against bacterial infection (Butler WT, Connect. Tissue Res. 23,123-136, 1989).

Osteopontin in laminae limitantes at bone surfaces may act as a substrate for osteoclast adhesion, and then for initial sealing zone attachment, during osteoclast migration and bone matrix resorbtion, respectively. During the reversal phase of the remodeling sequencing, the initial expression of osteopontin has been suggested to reflect the involvement of this non-

collagenous bone protein in cell-matrix interaction (Lian JB, Stein GS, Crit. Rev. Oral Biol. Med. 3, 269-305, 1992). Opn secreted early in the life cycle of differentiating preosteoblasts accumulates at the resorbed bone surfaces to form a cement line. The deposition of this planar arrangement of Opn
5 initially may serve to influence early matrix organization and mineralization, and possibly preosteoblasts adhesion at these sites. It also may function in a broader sense as a matrix-matrix/mineral biological glue to attach newly formed bone to older bone in order to maintain overall tissue integrity and biomechanical strength during bone remodeling (McKee MD, Nanci A,
10 Osteopontin and the bone Remodeling Sequence Colloidal-Gold Immunocytochemistry of an Interfacial Extracellular Matrix Protein, In: Osteopontin: Role in Cell Signaling and Adhesion. Annals of the New York Academy Sciences 760: April 21, 1995). Based on the sequence of appearance of matrix proteins, it may be postulated that Opn place a dual
15 role, first participating in cells attachment and then in the mineralization of the cement line-like material found in vivo (Shen X, Cells and Materials 3, 257-272, 1993).

3 Bonding Of Proteins To Titanium Surfaces

An implanted material attains and maintains contact with interfacial
20 tissue through its surface. When a substrate or an implant is inserted into the body environment, it is exposed to cells and a host of ionic and molecular species that ultimately determine the course of interfacial events (Kasemo B, J. Of Prosth Dent. 49(6):832-837, 1983). One of the first things to happen is the absorption of proteins onto the substrate (Kasemo B, J. Prosth Dent.
25 49(6):832-837, 1983). The absorption takes place within the first 10 to 60 seconds of contact, long before the cells get access to the surface. This means that any cells which interact with the alloplast surface can only do so indirectly, through the absorbed protein layer.

The nature and amount of protein absorbed is specific to the alloplast
30 composition (Uniyal S, Brash JL, Thromb. Haemost. 47, 285-290, 1982), depending on the physical and electromechanical properties of the given

surface. It is conceivable that the absorbed protein contingent could determine what kind of cells interact with the alloplast surface (Bagambisa FB et al., *Int. J. Oral Maxillof Implants* 5, 217-226, 1994). Cell contact with the substrate is maintained by the formation of subcellular spatially and morphologically defined adhesion sites called focal adhesions. Focal adhesion are within 15 to 30 nm proximity of the substrate (Izzard CS, Lochner RL, *J. Cell Sci.* 21:129-159, 1976) and are about 2 to 10 μ m long and 150 to 500 nm wide (Burridge K et al, *Ann. Rev. Cell Biol.*, 487-525, 1988). Although the different phenomenological response of cells to material surfaces has been attributed to wetability, this can only be a first approximation (Parsegian VA, *J. Of Prosth Dent.* 49(6):838-841, 1983). It appears more useful to talk about the ability of the surfaces to interact with the key molecules involved in the orchestration of the post implantation interfacial events. If a material surface can not bind the macromolecules supportive of osteoblast function, the material is not likely to make a good bone implant. One way of getting bone cells to appose bone tissue onto the implant surface might be through having or creating surfaces that are attractant to the macromolecules responsible for events like cell phenomenology, growth and differentiation (Bagambisa FB et al. *Int. J. Oral Maxillof. Implants* 5:217-226, 1994).

The absorption onto Ti of aqueous solutions of matrix or matrix-like proteins has resulted in significant increases in the number of cells bound. This effect has been reported (Burridge K et al. *Ann. Rev. Cell Biol.* 487-525, 1988) and indicates that a specific cell receptormatrix protein interaction is a more efficient means of attachment than the undefined process of cell-Ti interaction.

Histological information is available on the interface between bone and implant material, but the understanding of the mechanisms operating when an implant is inserted into bone is limited and the concepts are speculative.

The process of integration is going on in an aqueous environment. When two bodies make contact, it is because they prefer each other to the intervening water or whatever else is originally between them. In the vicinity of an electrical charge, a molecule will turn to keep its attractive end close to the intruding charged body (Parsegian VA, J. Prosth Dent. 5 49(6):838-841, 1983). Small amounts of positively charged calcium ion will bind to certain electrically negative surface groups, displacing the water and replacing it with a bridge of (-) (+), (+) (-) configurations between bilayers. Exponentially decay repulsion seen between bilayer membranes is seen 10 also between single molecules (Parsegian VA, J. Prosth Dent. 49(6):838-841, 1983).

There are two paths in which a range of close interaction can be analyzed: first, the list of hydrogen bonds, hydrophobic bonds, salt bridges, van der Waals forces. Second, direct inspection of molecular contacts are 15 they occur in protein monomers or tetramers the structures of which have been determined to atomic resolution by x-ray diffraction.

The metal surface is in fact a highly polarizable titanium oxide layer probably modified by accumulated impurities, from the bulk metal phase. With time, the titanium with oxide surface blends with material from 20 adjacent tissue, and a thin layer of ground substance of cellular origin is deposited on the implant so as to cement bone tissue and titanium. The interactions of principal importance probably are electrostatic rather than van der Waals or hydrophobic interactions (Parsegian VA, J. Of Prosth Dent. 49(6):838-841, 1983). To a charged body, the highly polar oxide layer 25 provides a strongly attractive alternative to water. The many configurations of titanium and oxygen likely to occur in such a surface provide a wide variety of adsorbant sites to attract various arrays of charge that probably reside on the water-soluble ground substance.

The oxide layer is so highly polar and therefore able to attract species 30 that are ordinarily water soluble. Positive electrical charges in particular will move toward the oxide, for in addition to its polarizability the layer is

negatively charged. It should not be surprising that such a highly polar region has been observed to incorporate (positive) calcium and (negative) phosphate ions from the adjacent aqueous phase. It is almost certain that the polar properties of adsorbant and substrate -not van der Waals forces, nor
5 generalized electrical doubled layer, nor hydrophobic attractions- will determine contact (Parsegian VA, J. Of Prosth Dent. 49(6):838-841, 1983).

The chemical property of the titanium oxide surface suggests that calcium ions may be attracted to the oxide cover surface by electrostatic interaction with O- as just discussed. Calcium deposits have been observed
10 in direct contact with the titanium oxide (Albrektsson T, and Hansson HA, Biomaterials, 7,201-205, 1986). According to the same model, calcium binding macromolecules may absorb selectively to the implant surface in vivo as the next sequence of events. Calcium binding molecules are often acidic with surface exposed carboxyl, phosphate or sulphate groups.
15 Proteoglycans and/or proteins containing carboxyl and phosphate/sulphate groups may bind to the TiO₂ surface by this mechanism. Hydroxyapatite, the major mineral component of bone, also exhibits a surface dominated by negatively charged oxygen (P-bound) that can attract cations and subsequently anionic calcium binding macromolecules (Bernardi G and
20 Kawasaki T, T: Chromatography of polypeptides and proteins on hydroxyapatite columns, Biochim. Biophys. Acta. 160, Pp 301-310, 1968). Glycosaminoglycans interact electrostatically with hydroxyapatite surface (Embery G and Rolia G, Interaction between sulphated macromolecules and hydroxyapatite studied by infrared spectroscopy. Acta Odontol. Scand, 38,
25 105-108, 1980). It has been shown that calcium absorbs to the surfaces after treatment with CaCl₂. The absorption of calcium onto the titanium implant surface when exposed to body fluids, increase its biocompatibility with bone and induce a subsequent adsorption of calcium binding macromolecules on to the implant surface. The surface characteristics of TiO₂ probably change
30 from an anionic to a cationic state by the adsorption of calcium to the surface which will be subsequently have an increased ability to absorb acidic

macromolecules like Opn. The results of the study were consistent with the proposal that calcium binding is a major mechanism by which proteins adsorb to TiO₂.

5 The present invention is further illustrated by the following non-limiting examples.

Example 1: Coating of Implants

Titanium, plastic, glass and chromocobalt (CrCo) surfaces were coated with human recombinant OPN. Attachment and proliferation of human osteoblasts by means of matrix formation markers was evaluated using uncoated surfaces as a control. Also the amount of adhesion protein that can be coated to these surface was investigated.

15 The human recombinant phosphorylated form of osteopontin (rhOpn) was used as an adhesion molecule. This form of osteopontin migrates on 10% SDS-gels with an apparent molecular weight of 78Kd, making it easy to differentiate from osteopontin secreted by osteoblasts which migrates in the same gels with an apparent molecular weight of 58Kd.

The experiments outlined below investigate the expression and mineralization of extra cellular matrix components in human osteoblasts cultured on titanium disks, plastic, glass and chromocobalt surfaces coated with recombinant osteopontin. The adhesion molecule rhOPN used as a coating for these surfaces enhances attachment and proliferation of human osteoblasts cell lines, and increases the expression of matrix components when compared against uncoated surfaces.

MATERIALS AND METHODS

25 Cell culture of human osteoblasts

50,000 cells from the human osteoblastic cell line were seeded onto sterile titanium disks (11 mm in diameter) or titanium disks coated with recombinant Osteopontin placed inside a 24 well plate (12 mm diameter well) (Costar, Cambridge, MA). Cells were initially maintained in Dulbecco's Modified Medium (DME) supplemented with 10% fetal bovine serum until reaching confluence. The cells were then grown in DME media

supplemented with 10% fetal bovine serum, 12.5ug/ml ascorbic acid and 5 mM B-glycerophosphate (denoted as complete media).

Determination of protein absorption onto Titanium surfaces.

Titanium disks were cleaned in 10% Nitric acid for 12 hours, washed
5 exhaustively with water, sterilized, then placed inside a 24 well plate (12 mm diameter well) (Costar, Cambridge, MA), and washed twice with 0.5ml of sterile PBS. 0.1 milimolar CaCl_2 was added to 8 disks. Four different concentrations of the human recombinant osteopontin (60, 200, 400, 600 ug) were labeled with S35, and placed on all the titanium disks. After 24 hours,
10 the bound and unbound protein was collected and counted using the Scintillation counter (Bergman 5000). The values among the two groups at the four concentrations were compared to determine the action of Calcium as a binding agent and the adequate concentration of the recombinant protein.

**The attachment of HOS cells as a function of the substrate they were
15 grown on.**

HOS cells were labeled overnight with 10 uCi ^3H -thymidine, then dissociated from the plate with non-enzymatic dissociation solution (Sigma), washed 2 times with PBS, and counted. ^3H -thymidine incorporated into TCA insoluble material was determined for the cells. 5000 cells (cpm total
20 1000) were plated onto coated or uncoated titanium disks and the disks incubated at 37°C for 30 min. Unadhered cells were removed, and attached cells were washed 3 times with 0.5 ml PBS. The cells were lysed with ice cold 20% TCA and the radioactivity in the TCA insoluble fraction was determined using the Scintillation counter (Begman 5000).

**The proliferation of HOS cells as a function of the substrate they were
25 grown on.**

Cell proliferation was determined by the rate of ^3H -Thymidine incorporation into DNA. Cells were labeled with 10 $\mu\text{Ci/ml}$ of ^3H -Thymidine in DME media. After 6 hours, the cells were lysed in cold
30 10% trichloroacetic acid (TCA). The TCA insoluble material was collected and washed several times with 10% TCA, then resuspended in 0.5 N NaOH.

³H-thymidine incorporation into TCA insoluble material was used as an index of cell proliferation. The material collected was mixed with scintillation liquid (Begman). The amount of radiation generated was compared between cells grown in titanium disks uncoated, and titanium disks coated with OPN.

Synthesis of osteopontin (Opn) and bone sialoprotein (BSP), and their secretion and deposition into the extracellular matrix.

Osteopontin and BSP were extracted from the extracellular matrix of HOS cells cultured on Ti disks or Ti disks coated with the recombinant Opn with lysis buffer (20 mM phosphate buffer, pH, 7.2, containing 150 mM NaCl, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride, 5mM benzamidine, 0.1 mM ϵ -amino caproic acid, 0.1 b-hydroxy mercuribenzoate, 0.1 mM pyrophosphate, 1mM sodium fluoride, 1mM sodium orthovanadate and 10 mM EDTA). Samples were then processed for Gel electrophoresis.

Western blot analysis: Cell layer proteins and conditioned media was electrophoresed in 10% SDS-polyacrylamide slab gels at 150 volts for 4h. For Western blot analysis resolved proteins in gels were transferred by semi-dry blotting onto nitrocellulose membranes (Schleicher & Schuell, Keene, NH), gel transfers were carried out for 90 min. at 12 V in 0.025 M Tris-glycine buffer, pH 8.2, containing 20% methanol and 0.01% Tween 20 and 10% nonfat dry milk, then incubated with rabbit anti-mouse osteopontin (Ashkar S, et al., New York Academy of Science 760:296-298, 1995) in 20 mM Phosphate buffer, pH 7.4, containing 150 mM NaCl, 0.1% Tween 20 and 1% nonfat dry milk. After 1h, the membranes were washed 3 times with 20mM Phosphate buffer, pH 7.4, containing 150 mM NaCl, 0.1 % Tween 20, then incubated with horseradish peroxidase-conjugated goat anti-rabbit Ig antibodies for 1h. Following several washing steps, the membranes were developed with ECL. Nonspecific interaction was assessed by the interaction of the primary and secondary antibodies with rabbit serum albumin.

Identification of proteins was made running the samples collected in a 7.5% SDS-polyacrylamide slab gels at 150 volts for 4h. Then, the gels were stained by immersion in Coomassie blue for 24 hours. The gel was washed with 10% Acetic Acid, 20% Methanol, 70% ddWater, and the proteins identified by molecular weight against the standards ran with the samples.

The expression of alkaline phosphatase enzyme activity on human osteoblast cell membranes in culture.

Alkaline phosphatase enzyme activity was determined in glycine buffer pH 10.2 using p-nitrophenol phosphate as described (Gerstenfeld LC et al., Develop Biol; 122:4940, 1987). Briefly, cell layer was extracted with NP 40 (Detergent) in PBS for 10 min. at 4°C. 100µl Aliquots were frozen until used. Then, the samples were thawed and prepare in glycine buffer plus p-nitrophenol phosphate for one hour at 37°C. After the samples turned yellow, the reaction was stopped with 0.2 milimolar Na OH, and the samples were read in the spechtometer (Begmann).

Determination of mineral content of human osteoblast cell culture.

HOS cells were grown either on coated or uncoated titanium disks. Media was supplemented with ascorbate and b-glycerol phosphate to stimulate the mineralization of the extracellular matrix. After two weeks, media was removed and the cells were lysed with triton. Then, all soluble components were removed and calcium content was determined using quantitative, colorimetric determination at 575 nm (Sigma Diagnostics Calcium). Basically, calcium reacts with o-cresolphthalein, a chromogenic agent that in an alkaline medium forms a purple colored complex. The intensity of the color, measured at 573 nm, is directly proportional to calcium concentration in the sample.

Determination of Peptides exhibiting binding and cell spread activity

Example 11 analyzes the binding and cell spread activity of various peptides. The activities were measured in 24-well plates that were coated overnight at 4°C with 10µg/ml of the indicated ligand or peptide and then blocked for one hour at room temperature with 10 mg/ml BSA (Bovine

Serum Albumin) in PBS (Phosphate Buffered Saline). To preserve the integrity of the adhesion receptors osteoprogenitor cells were harvested from sub-confluent cultures by non-enzymatic cell dissociation solution (Sigma, St. Louis, MO). Cells were washed twice with PBS and re-suspended at a concentration of 1×10^5 cells/ml of sterile Ca^{2+} - and Mg^{2+} -free PBS, supplemented with 0.1% BSA and 1mM sodium pyruvate. 5×10^4 cells were incubated in each well and, after one hour at 37°C , the wells were washed three times with 0.5 ml PBS to remove non-adherent cells, fixed in 1% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) at room temperature for one hour then stained with toluidine blue and hematoxylin. The total number of attached or spread cells in each well were counted microscopically using a Nikon Eclipse microscope equipped with a Sony digital camera. Total number of attached or spread cells were quantified using an Optima 5.2 image analysis system. Each experiment was done in triplicate and is reported as mean \pm standard error. To minimize variability inherent to cell attachment studies cells were scored as attached only when a defined nucleus observed accompanied by a transition from round to cuboidal cell morphology. Round cells that are loosely attached with no defined nucleus were scored as non-attached. These cells can be removed with repeated washes. The viability of the cells was measured before and after the termination of the experiments and only data from experiments with greater than 95% cell viability were used. Further, under the conditions used in these experiments, cell attachment was temperature dependent, inhabitable by trypsin treatment and not affected by inhibitors of protein synthesis or secretion. Cell spreading was determined by membrane contour analysis and was scored according to increase in cell volume/surface area. Because of this change in cell volume/surface area, cell spreading is a measure of a change in cellular development. In some experiments, cell spreading was also assessed by the formation of stress fibers. The formation of stress fibers and/or changes in cell volume/surface area are each characteristics of cells

undergoing differentiation. Each experiment was performed in quadruplicate wells and repeated three times.

Chemotaxis

Directed migration of cells (chemotaxis) are determined in multi-well chemotaxis chambers as described. (Weber et al. (1996) Science 26:271:509-512). Briefly, two-well culture plates (Transwell) with polycarbonate filters (pore size 8-12 μm) separating top and bottom wells were coated with 5 μg fibronectin. 2×10^5 cells are added to the upper chamber and incubated at 37°C in the presence or absence of the peptide of interest in the lower chamber. After 4h, the filters are removed, fixed in methanol, stained with hematoxylin and eosin and cells that migrate to various areas of the lower surface are counted microscopically. Controls for chemokinesis include 200ng of osteopontin in the top well. All assays are done in triplicate and reported as mean \pm standard deviation.

Haptotaxis

Haptotaxis of cell lines to peptides or fragments are assayed using a Boyden chamber. The lower surface or both sides of polycarbonate filters with 8 μm pore size were coated with different amounts of peptide. 2×10^5 cells are added to the upper chamber, and incubated at 37°C in the absence of any factors in the lower chamber. After 4h the filters are removed, fixed in methanol and stained with hematoxylin and eosin. Cells that migrate to the lower surface are counted under a microscope. All assays are done in triplicate and are reported as a mean \pm standard deviation.

Example 2: Effect of Ca^{++} ions on the binding of osteopontin to Ti disks.

Increasing concentration of ^{35}S -labeled OPN (60, 200, 400, 600 μg) were incubated with titanium disks either with (■) or without (✚) CaCl_2 at 40°C. After 24 h the unbound protein was removed and the Ti disks were washed with PBS. Bound OPN was extracted from the disks with scintillation fluid and counted. Each experiment was done in triplicates and reported as mean \pm SEM.

To investigate whether exogenously added Ca^{++} had any effect on the binding of rhOPN to Ti, the binding of rhOPN to Ti disks was measured with and without added CaCl_2 . The results, presented in Figure 1, demonstrate that in the absence of added CaCl_2 the Ti disks saturate at 60 μg of rhOPN, but in the presence of 100 mM CaCl_2 the Ti disks can bind more rhOPN saturating at more than 110 μg protein/disks.

Example 3: Attachment of HOS cells to Ti surfaces coated with rhOPN

5000 cells (total cpm 1000) were plated on either coated or uncoated Ti disks and incubated at 37°C in a humidified atmosphere (95% air 5% CO_2). After 30 min, unattached cells were removed and the disks were washed with PBS. The total number of attached cells was determined for the total cpm released for the disks after the cells were lysed with 10% TCA and solubilized in 5 ml scintillation fluid. All measurements were done in triplicates and graphed as mean \pm Standard error of the mean.

The initial events following seeding of cells onto Ti surfaces include the attachment, migration and proliferation of the seeded cells. Coating Ti disks with 50 μg of rhOPN enhanced by 1100% the attachment of HOS cells to Ti disks (Figure 2), after 30 min. These results are consistent with the role of osteopontin in promoting cell attachment and spreading.

Example 4: Proliferation of HOS cells on Ti surfaces coated with phosphorylated human recombinant Opn.

Cell proliferation was determined by the rate of ^3H -Thymidine incorporation into DNA. Cells labeled with ^3H -Thymidine were seeded for 6 hours, then lysed with TCA. The TCA insoluble material was collected and resuspended in 0.5 N NaOH. ^3H -thymidine incorporation into TCA insoluble material was used as an index for cell proliferation. Rate of proliferation is expressed as cpm/1000 cells/6h. Control group: 254,54, rhOPN group: 560,83. All measurements were done in triplicates and reported as mean \pm Standard error for the mean.

Since rhOPN promoted cell attachment to Ti disks, it was of interest to examine whether the protein had any effect on the proliferation of HOS

grown on Ti disks. Measurement of the rate of proliferation of HOS cells grown on coated or uncoated Ti disks showed that the proliferation rate of cells grown on rhOPN coated Ti disks was approximately twice (Figure 3) the proliferation rate of cells grown on uncoated Ti disks.

5 **Example 5: Secretion of osteopontin and BSP by HOS cells growing on coated Ti disks.**

Cell layer proteins and conditioned media was electrophoresed in 10% SDS-polyacrylamide slab gels at 150 volts for 4h. The resolved proteins were transferred by semi-dry blotting onto nitrocellulose membranes
10 for 90 min. at 12 V in Transfer Buffer. Then, the membranes were incubated with either rabbit anti-mouse osteopontin or rabbit anti-mouse BSP. After 1 h, the membranes were washed 3 times with PBST. Then incubated with horseradish peroxidase-conjugated goat anti-rabbit Ig antibodies for 1h. Following several washing steps in PBST, the membranes were developed
15 with ECL as described by the manufacturer (Amersham, London).

Osteopontin and BSP were extracted from the extracellular matrix of HOS cells cultured on Ti disks or Ti disks coated with the recombinant Opn with lysis buffer. Samples were then processed for Gel electrophoresis. Western blot analysis for OPN secretion into the extracellular matrix showed
20 increased secretion of OPN from cells grown on coated Ti disks when compared to cells grown on uncoated titanium controls as denoted. Assays for Opn expression by Western blot were done by triplicate.

BSP extracellular matrix secretion expressed by Western blot analysis was less marked than the production of osteopontin from cells grown on the
25 rhOPN coated implants. Cells in the control groups did not expressed bone sialoprotein. Assays for BSP expression by Western blot were done by triplicate.

Example 6: Expression of alkaline phosphatase enzyme activity on human osteoblast cell membranes in culture.

30 Alkaline phosphatase enzyme activity was determined in glycine buffer pH 10.2 using pnitrophenol phosphate. Cell layer was extracted with

NP 40 in PBS for 10 min. at 4°C. 100µl Aliquots were used. The alkaline phosphatase activity determined by colorimetric assay (as described in materials and method). A unit is defined as the amount of enzyme which releases 1 µmol of p-nitrophenol/h. All measurements were done in triplicates and reported as mean ± Standard error of the mean.

Since secreted proteins and extracellular matrix production was different between cells grown on coated and uncoated disks, the levels of alkaline phosphatase in both groups were examined to assess the extent of differentiation of HOS cells grown on coated Ti Surfaces. The results presented in Figure 4, indicate that the levels of alkaline phosphatase activity in cells grown on Ti disks decreased over the levels of Apose detected in the control groups. These results are consistent with the observations that Apose activity decreases as osteoblasts differentiate into mature matrix producing cells.

Example 7: Extracellular matrix mineralization of HOS cells grown on either coated or uncoated Ti.

HOS cells were grown either on coated or uncoated titanium disks. Media was supplemented with ascorbate and β-glycerol phosphate. After two weeks, media was removed and the cells were lysed. Then, all soluble components were removed and calcium content was determined using quantitative, colorimetric determination at 575 nm (Sigma Diagnostics Calcium). All measurements were done in triplicates and reported as mean ± Standard error in the mean.

When cultured in the presence of ascorbate and β-glycerol phosphate, HOS cells grown on coated Ti disks mineralized their extracellular matrix within 2 weeks (Figure 5) in a manner similar to HOS cells cultured on plastic. However, HOS cells grown on uncoated Ti disks under similar conditions did not mineralize their extracellular matrix. These results and the results presented above suggest that when cultured on uncoated Ti disks HOS cells attach, proliferate and differentiate at a slower rate than when cultured on coated disks. Furthermore, HOS cultured on coated disks

synthesize an extracellular matrix that mineralizes within two weeks. In several respects HOS cells grown on Ti surfaces coated with rhOPN develop in a manner similar to cells grown on plastic dishes.

Example 8: Attachment of HOS cells to surfaces coated with OPN

5 500 cells were plated on coated plastic, glass or chromocobalt surfaces and incubated at 37°C in a humidified atmosphere (95% air 5% CO₂). Surfaces were coated with either human recombinant phosphorylated OPN (rhOPN) or unphosphorylated OPN. Fibronectin coated surfaces were used as a control. After 1 hour, unattached cells were removed and the
10 surfaces were washed with PBS. The total number of attached cells was determined for the total cpm released for the surfaces after the cells were lysed with 10% TCA and solubilized in 5 ml scintillation fluid. All measurements were done in triplicates. The results are outlined in Table 2 below.

15 TABLE 2: Attachment of HOS Cells to OPN coating.

Surface	% total attached
Plastic	
OPN	43.6
OPN-p	90.8
Fibronectin	91.6
glass	
OPN	37.2
OPN-p	98.1
fibronectin	89.6
chromocobalt (CrCo)	
OPN	4
OPN-p	69.2
fibronectin	54.8

OPN = unphosphorylated OPN

OPN-p = phosphorylated OPN

5 The results outlined above demonstrate that human recombinant phosphorylated OPN (rhOPN) promoted cell attachment at the same or higher rate than fibronectin. These results are consistent with the role of osteopontin in promoting cell attachment and spreading.

Example 9: Proliferation of HOS cells on surfaces coated with phosphorylated human recombinant Opn.

10 Cell proliferation was determined by the rate of ^3H -Thymidine incorporation into DNA. Cells labeled with ^3H -Thymidine were seeded for 6 hours, then lysed with TCA. The TCA insoluble material was collected and resuspended in 0.5 N NaOH. ^3H -thymidine incorporation into TCA insoluble material was used as an index for cell proliferation. Rate of
15 proliferation is expressed as cpm/1000 cells/6h. All measurements were done in triplicates.

Since rhOPN promoted cell attachment to different surfaces, it was of interest to examine whether the protein had any effect on the proliferation of HOS grown on these surfaces. Measurement of the rate of proliferation of
20 HOS cells grown on coated or uncoated glass, plastic and chromocobalt surfaces showed that the proliferation rate of cells grown on rhOPN coated surfaces was at least twice (Table 3) the proliferation rate of cells grown on uncoated surfaces.

TABLE 3: Proliferation of HOS Cells on OPN

Surface	Proliferation Rate (Rate Cpm/6h/1000 cells)
Plastic only	1100
Plastic + rhOPN	3300
Glass only	310
Glass + rhOPN	2740
CrCo only	120
CrCo + rhOPN	1740

Example 10: *In Vivo* Studies of Ti coated rhOPN implants

5 Forty implants (5 per quadrant) were placed in four
Haundel/Labrador dogs after extraction of four premolars (PM1-PM4) and
one molar (M1), and a three month healing period. Eight hollow screw Ti
implants were coated with rhOPN. Eight uncoated implants served as
controls. The remaining implants were coated with 3 additional different
10 molecules denoted as study 2, study 3, and study 4.

Prior to implant placement, core samples from the donor place were
taken to histologically analyze bone quality after extractions. This
procedure, also ensured a hollow space for bone ingrowth inside the coated
and uncoated implants. Dogs were sacrificed after 4 and 8 weeks.

15 Implants were recovered for histological analysis. Each implant was
sectioned vertically. The core inside the hallow implant was removed using
liquid nitrogen. Decalcified sections were embedded in paraffin and stained
using Herovichi's techniques to differentiate immature from mature collagen.
Light microscopy at 4X and 40X magnifications were used to compare
20 histological differences between rhOPN coated implants and uncoated
implants.

The *in vivo* results show enhanced bone healing around coated implants. Uncoated implants show normal bone healing characterized by granulation tissue and a few areas of vascularization and matrix deposition after four weeks. These results demonstrate that coating titanium implants with rhOPN reduces healing time around dental implants.

Example 11: *In vivo* Studies of implants coated with recombinant osteopontin (rOPN) or mOC-1016 (SEQ ID NO:15).

Since titanium does not induce bone formation, one way of assuring the apposition of bone cells to the implant is to design an implant surface that is attractant to these molecules. The present Example evaluates the enhancement of osseointegration of dental implants coated with either osteopontin or mOC 1016 (SEQ ID NO:15) as compared to non-coated titanium plasma sprayed (TPS) surface in a canine model. Canine models allow the use of implant designs and sizes commonly used in clinical applications.

Mandibular premolars and first molars were extracted bilaterally in a total of twelve dogs. After a healing period of three months, 6 implants TPS (ITI 4.1 x 8 mm) were placed in each mandibular quadrant. Test coatings of rOPN and mOC-1016 and non-coated TPS control were used. A randomized distribution of tests and controls were incorporated. Test solutions were comprised of mannitol, sucrose, citric acid, water and OPN and OC-1016.

Large hounds were used in this Example. For all surgical procedures (extractions, implant placement, suture removal), after sedation with acepromazine (0.1 mg/kg S.C.), the animals were anesthetized using pentobarbital (20mg/kg I.V.). Antibiotics (bicillin 200,000u I.M.) and ibuprofen for pain control (200mg/dog/day P.O.) were given for extraction and implant placement surgeries. For sacrifice, an overdose of pentobarbital (50mg/kg I.V. after sedation with acepromazine 0.1 mg/kg S.C.) was administered.

The implant and its surrounding tissue were dissected in block, fixed in 4% formaldehyde and imbedded in PMMA. The osseointegration of the

implant was measured as percent of directly apposed bone versus total implant area by contour analysis using an image analysis system. The extent of new mineralized bone (in percent) in the area between the major and minor diameter of the implant was also determined.

5 Assessment of the bone to implant contact (BIC) at 4 weeks indicated that the implants treated with rOPN or mOC-1016 had significantly greater BIC than non-coated implants (Table 4). Mean percent bone to implant contact was 45.00, 65.6, 61.3, 64.9, 73.1, and 70.3% in the non-coated implants, rOPN at 200 µg/ml, and mOC-1016 25, 50, 100 and 200 µg/ml
10 groups respectively. At the 12 week time point, the treatment groups again had greater bone to implant contact when compared to non-coated implants (Table 5). Mean percent bone to implant contact was 46.5, 62.5, 58.3, 54.7, 60.5, and 59.7% in the non-coated implants, rOPN 200µg/ml, and mOC-1016 25, 50, 100 and 200 µg/ml groups respectively. The rOPN 200µg/ml
15 had statistically significant greater BIC when comparing to uncoated implants at 12 weeks.

 The bone density surrounding the implants at 4 weeks post-implantation have been summarized in Table 6. Mean percent bone density was 54.5, 70.9, 67.8, 69.3, 76.9, and 72.6% in the non-coated implants,
20 rOPN at 200µg/ml, and mOC-1016 25, 50, 100 and 200 µg/ml groups respectively. The difference between the response of all treatment were statistically significantly greater than the non-coated implant group. The 12-week bone density results indicate a statistically significant difference among the treatment groups (Table 7).

25 The *in vivo* results outlined above indicate that OPN and mOC-1016 are able to accelerated the healing of dental implants in the canine model. Bone to implant contact percentages were statistically greater in the treatment groups compared to the untreated implants at 4 weeks. The rOPN and mOC 1016 treated dental implants were able to improve the density of
30 bone as compared to untreated implants. Bone density percentages were statistically greater in the treatment groups when compared to the untreated

implants at 4 weeks. At 12 weeks post-implantation, OPN and mOC-1016 treated implants were significantly different when compared to non-coated implants.

The issue of safety was also addressed by assessing the serum chemistry, hematology and antibody results following treatment. These safety assessments indicate that there are no clinically significant differences from baseline. Therefore, rOPN and OC-1016 are safe based upon these evaluations.

The results outlined above also demonstrate that coating of different surfaces, e.g., titanium disks, glass, plastic, or CrCo, with phosphorylated human recombinant osteopontin enhances the rate of attachment and proliferation of human osteoblast cell lines *in vitro* when compared to uncoated surfaces. This enhancement is demonstrated by better attachment and proliferation of the cells, increased production of the extracellular matrix components, and its faster calcification. These results also contribute to the understanding of the molecular events that may be occurring in the healing of bone around the implants.

Table 4: Mean Percent Bone to Implant Contact at 4 Weeks

	Mean	SEM	SD
TPS	45.0	3.5	12.1
OPN 200µg/ml	65.6	2.8	9.6
OC-1016 25µg/ml	61.3	3.0	10.3
OC-1016 50µg/ml	64.9	3.3	11.4
OC-1016 100µg/ml	73.1	3.1	10.8
OC-1016 200µg/ml	70.3	2.9	10.2

Table 5: Mean Percent Bone to Implant Contact at 12 Weeks

	Mean	SEM	SD
TPS	46.5	1.7	5.5
OPN 200µg/ml	62.5	3.2	10.1
mOC-1016 25µg/ml	58.3	2.9	9.2
mOC-1016 50µg/ml	54.7	5.0	15.7
mOC-1016 100µg/ml	60.5	3.6	10.7
mOC-1016 200µg/ml	59.7	2.9	9.1

Table 6: Mean Percent Bone Density at 4 weeks

	Mean	SEM	SD
TPS	54.5	2.5	8.6
OPN 200µg/ml	70.5	3.7	12.9
mOC-1016 25µg/ml	67.9	4.8	16.5
mOC-1016 50µg/ml	69.3	3.4	11.7
mOC-1016 100µg/ml	76.9	3.0	10.3
mOC-1016 200µg/ml	72.6	3.5	12.1

Table 7: Mean Percent Bone Density at 12 Weeks

	Mean	SEM	SD
TPS	58.7	3.5	11.1
OPN 200µg/ml	56.9	5.4	17.0
MOC-1016 25µg/ml	65.8	3.8	12.1
MOC-1016 50µg/ml	56.9	5.1	16.1
MOC-1016 100µg/ml	63.5	4.4	13.2
MOC-1016 200µg/ml	57.9	3.0	9.6

Example 12: Peptide binding and cell spread.

5 5000 total human osteoprogenitor cells were plated on either uncoated plates or coated and incubated at 37°C in a humidified atmosphere (95% air, 5% CO₂). After 30 minutes, unattached cells were removed and the plates were washed with PBS. The total number of attached cells was determined as described in the materials and methods. In some experiments
10 (labeled with an "#" in Table 8), antibodies (0.1µg/ml) against various integrins were incubated with the cells for 15 minutes prior to plating.

When coated with osteopontin, mOC-1016 (SEQ ID NO:15), SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, or SEQ ID NO:14, plates coated with human osteoprogenitor cells undergo a
15 transformation from a neutral (uncoated condition) to a proactive condition in which the number of attached cells, as well as the percent spread, significantly increases (Table 8). Table 8 also illustrates that antibodies to different integrins may be used to block binding to specific integrins. For example antibodies to $\alpha_v\beta_3$ integrin significantly diminish mOC-1016
20 binding (See Table 8). Such antibodies may be used to abolish or attenuate the activity of specific peptides, like OC-1016, *in vivo*.

Table 8 also provides evidence that peptides mOC-1016 (SEQ ID NO:15), SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14, each bind to osteoprogenitor cells and

significantly increase cellular attachment over the control. These same peptides also regulate cellular development of human osteoprogenitor cells by increasing the percentage of "cell spread". As noted in the material and methods, cell spread is measured by the change in cell volume to surface area, as well as the formation of stress fibers. Changes in morphological characteristics such as these, indicate that the cell is undergoing significant genetic and biochemical changes and being directed to the next step in the developmental pathway towards a differentiated phenotype.

Table 8: Peptide binding and cell attachment.

	% total attached cells	STD	% Spread	STD
Control	43.6	6.54	8.4	0.924
Osteopontin	78.4	11.76	78.4	9.408
SEQ ID NO:15	91.6	13.74	84.4	16.88
# Anti- $\alpha_v\beta_3$				
Control	31.2	4.68	5.2	0.52
Osteopontin	69.2	10.38	24.8	4.464
SEQ ID NO:15	48	7.2	12.4	1.24
# Anti-CD44				
Control	18.8	2.82	6.8	1.02
Osteopontin	66	9.9	46.4	7.888
SEQ ID NO:15	96.4	14.46	86.8	13.02
# Anti- $\alpha\beta_1$				
Control	23.7	3.792	7.1	1.065
Osteopontin	74.8	11.968	56.6	8.49
SEQ ID NO:15	96.8	15.488	89.3	13.395

Control	22.6	4.17	3.0	1.5
SEQ ID NO:9	66.6	12.8	54.4	6.45
Control	22.6	4.17	3.0	1.5
SEQ ID NO:10	98.8	21.7	77.9	13.2
Control	22.6	4.17	3.0	1.5
SEQ ID NO:11	84.6	9.7	91.6	6.4
Control	22.6	4.17	3.0	1.5
SEQ ID NO:12	73.9	12.2	88.6	13.7
Control	22.6	4.17	3.0	1.5
SEQ ID NO:13	91.1	20.6	100.0	2.8
Control	22.6	4.17	3.0	1.5
SEQ ID NO:14	90.0	9.7	99.2	11.5

Example 12: C-terminus of Osteopontin binds Eosinophils

White blood cells are grouped into three major categories, granulocytes, monocytes, and lymphocytes.

- 5 Lysosomes and secretory vesicles are the main components of granulocytes. Based on the morphology and staining properties of these organelles, granulocytes are subdivided into three more categories, neutrophils, which serve to phagocytose bacteria; basophils, which aid in inflammatory reactions by secreting histamine, and eosinophils, which
- 10 destroy small organisms and mediate allergic inflammatory responses.

Selective binding data has revealed that peptides comprising the C-terminal 59 amino acids of osteopontin are able to bind eosinophils *in vitro*.

The sequence is identified as

EHSDVIDSQELSKVSREFHSHEFHSHEDMLVVDPKSKEEDKHLKFRIS

HELD SASSEVN (SEQ ID NO:16). The binding data has been obtained using the cell attachment and spreading assays described above in the Material and Methods.

One will notice that the peptide does not contain an "RGD" sequence.

5 As discussed above, interactions via integrins and other receptors with the extracellular matrix are critical to the infiltration and accumulation of eosinophils in many diseases. Peptides lacking an RGD sequence yet harboring further sequence similarities to the amino acid sequence of SEQ ID NO:15 are of particular interest because such peptides contradict previous
10 evidence suggesting that the RGD sequence is necessary for binding to integrin receptors. Peptides such as these may be used to develop therapies for the treatment of such eosinophil-associated diseases listed above. For example, the peptide may be modified such that binding to the cell inhibits interaction with extra-cellular matrix (ECM) components and therefore
15 migration.

Example 13: Antibodies to SEQ ID NO:8 (OC 1016) and SEQ ID NO:15 (mOC-1016)

Antibodies are very selective proteins that are able to bind a single target among many. A major limitation in the therapeutic use of a particular
20 antibody is producing it in a large enough quantity to be useful. Advances in monoclonal antibody technology have provided a route to be used to secure significant amounts of these useful diagnostic and therapeutic proteins. The antigen of interest is injected into a mouse in order to elicit an immune response. Lymphocytes, another type of white blood cell that produce
25 antibodies, are stored in the spleen of the animal. The spleen is removed and the cells are fused to a specialized myeloma cell line. The fused cells (hybridomas) now produce antibodies specified by the lymphocytes from the immunized animal. These hybridomas also retain characteristics of myeloma cells, in that they continue to grow and divide in culture, producing a
30 relatively unending supply of antibody.

This monoclonal antibody technology has allowed for the production of antibodies against OC-1016 and modified OC-1016. Two hybridoma cell lines have been produced to generate antibody against OC-1016 and modified OC-1016 and are denoted herein as HYB 1016(a) and HYB 1016(b).

Example 14: Regulating Osteopontin expression

Additionally, two more cell lines have been established in which human osteopontin is under the control of a CMV (cytomegalo virus) promoter. These cell lines are human osteoblasts (Table V). Methods used to generate these cell lines are familiar to one of skill in the art and can be employed using conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology. The literature is replete with such techniques. See, for example, *Molecular Cloning A Laboratory Manual*, 2nd Ed., by Sambrook, Fritsch, and Maniatis (Cold Spring Harbor Laboratory Press: 1989); *DNA Cloning*, Volumes I and II (D.N. Glover ed., 1985); *Handbook of Experimental Immunology*, Volumes I-IV (D.M. Weir and C.C. Blackwell, eds., 1986); and *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

The cell lines presented here may be used to regulate the expression of human osteopontin. The expression of osteopontin *in vivo* varies and its presence in migrating fibroblastic cells complicates an understanding of its expression pattern even further. Zohar *et al.*, 1997, *Cell Physiol.* 170:88-100.

It is clear that osteopontin plays an indirect yet significant role in regulating the expression of developmentally regulated genes. By providing an osteoblast cell line in which the expression of osteopontin at a high level and constitutive, one is able to determine the effects of this expression of a developmentally critical ligand on the development of, for example, osteoblasts into osteocytes and lining cells. Once this is determined, therapies are developed to address issues associated with bone remodeling and periodontal disease. One is able to further regulate cellular

differentiation/development *in vivo* by expressing osteopontin that is produced and secreted by neighboring cells. Examples of cells harboring such an osteopontin expressible construct are osteoprogenitor cells, tumor cells, macrophages, periosteal cells, endothelial cells, epithelial cells, eosinophils, stem cells, osteoblasts, osteocytes, cementoblasts, fibroblasts, limited potential precursor cells, precursor cells, committed precursor cells, and differentiated cells.

One of skill in the art will recognize that the expression of osteopontin is not limited to constitutive expression driven by a CMV promoter. The expression of osteopontin may also be regulated using nucleic acid constructs harboring any number of available heterologous regulatable promoters. Heterologous is used herein to describe any promoter other than the native osteopontin promoter. The two cell lines described herein are referred to as HOBOP1 (Clone 1a - Human osteoblasts expressing hOPN1a under the control of CMV promoter) and HOBOP1 (Clone 2a - Human osteoblasts expressing hOPN1a under the control of CMV promoter).

We claim:

1. An osteopontin-derived peptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 7; SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO: 15..
2. The peptide of claim 1 regulating cellular development.
3. The peptide of claim 2, wherein the peptide binds to at least one receptor on a cell surface.
4. The peptide of claim 3, wherein the receptor(s) is an integrin.
5. The peptide of claim 4, wherein the integrin(s) is selected from the group consisting of $\alpha_v\beta_3$, $\alpha_v\beta_5$, $4\beta_1$, $2\beta_1$, VCAM, ICAM, CD44, V_3V_x .
6. The peptide of claim 3 wherein the cell is selected from the group consisting of osteoprogenitor cells, tumor cells, macrophages, periosteal cells, endothelial cells, epithelial cells, eosinophils, stem cells, limited potential precursor cells, precursor cells, committed precursor cells, and differentiated cells.
7. The peptide of claim 6, wherein the peptide does not contain an RGD motif.
8. An implant, comprising;
a material suitable for use *in vivo* within a subject in combination with an osteopontin-derived peptide forming an osteopontin-derived peptide containing implant.
9. The implant of claim 8 wherein the osteopontin-derived peptide is non-covalently attached to the material.
10. The implant of claim 3 wherein the non-covalent attachment of the osteopontin-derived peptide to the material is via a divalent ion bridge or via coating of a mucopolysaccharide on to the material.
11. The implant of claim 8 wherein the osteopontin-derived peptide possesses a cell attachment activity.


12. The implant of claim 10 wherein the osteopontin-derived peptide comprises an amino acid sequence selected from the group consisting of VFTPVVPTVDITYDGRGDSVVYGLRSKSKKFRRP (SEQ ID NO: 7); RSRRATEVFTPVVPTVDITYDGRGDSVVYGLRSKSKKFRRP (SEQ ID NO: 8); and acetyl-RSRRATEVFTPVVPTVDITYDGRGDSVVYGLRSKSKKFRRP (SEQ ID NO:15).
13. The implant of claim 8 comprising:
a releasable form of phosphorylated osteopontin or an active fragment thereof or a peptide derived therefrom in combination with titanium suitable for use *in vivo* within a subject.
14. The implant of claim 13 wherein the titanium implant is a dental implant.
15. A method of coating an implant with an osteopontin or an active fragment thereof or a peptide derived therefrom comprising:
attaching osteopontin or an active fragment thereof or a peptide derived therefrom to a surface of an implant,
wherein the osteopontin or an active fragment thereof or a peptide derived therefrom is attached to the surface of the implant such that it is releasable from the surface upon implantation into a subject.
16. An osteopontin containing cell recruitment system comprising:
a releasable osteopontin or a fragment thereof or a peptide derived therefrom in a form which provides a gradient; and
an implant forming a cell recruitment system in the proximity of the implant,
wherein the implant is targeted for cell recruitment by a gradient of osteopontin which forms in the proximity of the implant.



17. A method for inducing new tissue formation in a subject at a site where tissue formation is needed comprising:



adding osteopontin or a fragment thereof or a peptide derived therefrom to a subject at a site where tissue formation is needed, wherein the osteopontin or a fragment thereof or a peptide derived therefrom induces new tissue formation about the site.

18. A method for promoting cell differentiation, comprising administering to an animal or human a therapeutically effective amount of a peptide wherein the peptides bind to cells and produce developmental changes in the cell.

1/3

*FIG. 1*

**FIG. 2****FIG. 3**

*FIG. 4**FIG. 5*

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 April 2002 (25.04.2002)

PCT

(10) International Publication Number
WO 02/032940 A3

(51) International Patent Classification⁷: **A61L 27/22**,
A61C 8/00, C07K 14/52, A61K 38/19

(21) International Application Number: PCT/US01/32457

(22) International Filing Date: 18 October 2001 (18.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/241,248 18 October 2000 (18.10.2000) US
60/327,273 5 October 2001 (05.10.2001) US

(71) Applicant: **CHILDREN'S MEDICAL CENTER CORPORATION** [US/US]; 300 Longwood Avenue, Boston, MA 02115 (US).

(72) Inventors: **ASKAR, Samy**; 12 Stoneholm Street, Apartment 606, Boston, MA 02115 (US). **SALCEDO, Jairo**; 400 Brookline Avenue, Apartment 3A, Boston, MA 02115 (US).

(74) Agents: **PABST, Patrea, L.** et al.; Holland & Knight LLP, One Atlantic Center, Suite 2000, 1201 West Peachtree Street, Atlanta, GA 30309-3400 (US).


(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

[Continued on next page]

(54) Title: OSTEOPONTIN-COATED SURFACES AND METHODS OF USE



(57) Abstract: An osteopontin containing implant which increases the rate of osseointegration and the percentage of bone apposition is described. In one embodiment, the implant includes osteopontin or an active fragment thereof or an active peptide derived therefrom. In another embodiment, the implant includes a material suitable for use *in vivo* within a subject in combination with a releasable form of osteopontin forming an osteopontin containing implant. The disclosed osteopontin derived peptides bind to various cell types and play important roles in cellular differentiation and/or motility. Many of these interactions are mediated by integrins as disclosed. Antibodies provide a mechanism to abolish or attenuate the activities of the claimed peptides.



WO 02/032940 A3



- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
- *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(88) Date of publication of the international search report:
19 September 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/32457

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61L27/22 A61C8/00 C07K14/52 A61K38/19

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K A61L A61C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EMBL, EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,L	WO 99 08730 A (CHILDRENS MEDICAL CENTER) 25 February 1999 (1999-02-25) Throws doubt on the priority rights of the application, in particular the subject matter of claims 8-11 and 13-17 page 2-5; claims 1-3,5,20-22,24; example 9 ---	1,2,8-18
X	SMITH LAURA L ET AL: "Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha-9-beta-1 integrin." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 45, 1996, pages 28485-28491, XP002201290 ISSN: 0021-9258 page 28487; figures 1,3,4A,5B --- -/--	1,3-6

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

1 July 2002

Date of mailing of the international search report

23/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Brouns, G

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/32457

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! 14 May 1990 (1990-05-14) BORYSIEWICZ L. ET AL.: "Isoform of human osteopontin protein" retrieved from E.B.I, HINXTON, UK Database accession no. AAR30701 XP002201345 abstract -& WO 92 22316 A (UNIV CAMBRIDGE; UNIV PENNSYLVANIA (US); PHILADELPHIA CHILDREN HOSP) 23 December 1992 (1992-12-23) page 38-39</p> <p>---</p>	1
A	<p>SENGER DONALD R ET AL: "Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin." BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1314, no. 1-2, 1996, pages 13-24, XP002201291 ISSN: 0006-3002 abstract; figures 2-8</p> <p>---</p>	1-6
A	<p>DIJK VAN S ET AL: "EVIDENCE THAT A NON-RGD DOMAIN IN RAT OSTEOPONTIN IS INVOLVED IN CELL ATTACHMENT" JOURNAL OF BONE AND MINERAL RESEARCH, NEW YORK, NY, US, vol. 8, no. 12, 1 December 1993 (1993-12-01), pages 1499-1506, XP002047131 ISSN: 0884-0431 abstract; figures 4,6</p> <p>---</p>	1-6
A	<p>DATABASE EMBL 'Online! 9 October 1990 (1990-10-09) TERMINE J: "Sequence of human osteopontin II" retrieved from E.B.I., HINXTON, UK Database accession no. AAR05162 XP002201346 abstract -& US 5 340 934 A (TERMINE JOHN D ET AL) 23 August 1994 (1994-08-23) figure 4B</p> <p>---</p> <p style="text-align: center;">-/--</p>	1

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/32457

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE EMBL 'Online! 10 January 1990 (1990-01-10) CANTOR HI ET AL.: "Recombinant activation protein-1" retrieved from E.B.I, HINXTON, UK Database accession no. AAP91468 XP002201347 abstract -& WO 89 07613 A (DANA FARBER CANCER INST INC) 24 August 1989 (1989-08-24) figure 2B</p> <p>----</p>	1
A	<p>DATABASE EMBL 'Online! From patent W08902461-A/6, 23 April 1993 (1993-04-23) "Synthetic fusion protein SA341/1" retrieved from E.B.I, HINXTON, UK Database accession no. A03886 XP002201348 abstract -& WO 89 02461 A (SCHERING AG) 23 March 1989 (1989-03-23) figure 3B</p> <p>-----</p>	1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/32457

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 17 and 18 are directed to a method of treatment of the human or animal body, the search has been carried out and based on the alleged effects of the implant coated with the osteopontin derived peptide.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-18, in part, as far as applicable

Invention 1

An osteopontin-derived peptide comprising the sequence defined by SEQ ID NOS:7, in an implant, in a method of coating an implant, in an osteopontin containing cell recruitment system, in a method for inducing new tissue formation and in a method for promoting cell differentiation using a peptide

2. Claims: 1-18, in part, as far as applicable

Inventions 2-9

as in invention 1, but limited to the subject-matter relating to SEQ ID NOS:8-15, whereby

invention 2 is limited to an osteopontin-derived peptide defined by SEQ ID NO:8,
invention 3 is limited to an osteopontin-derived peptide defined by SEQ ID NO:9,
... and
invention 9 is limited to an osteopontin-derived peptide defined by SEQ ID NO:15

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No
PCT/US 01/32457

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9908730	A	25-02-1999	AU 8783798 A CA 2300194 A1 EP 1003570 A1 JP 2002500898 T WO 9908730 A1	08-03-1999 25-02-1999 31-05-2000 15-01-2002 25-02-1999
WO 9222316	A	23-12-1992	US 5304496 A AU 2186392 A WO 9222316 A1	19-04-1994 12-01-1993 23-12-1992
US 5340934	A	23-08-1994	NONE	
WO 8907613	A	24-08-1989	US 5049659 A AU 628806 B2 AU 3192989 A DK 189090 A EP 0406257 A1 JP 3502453 T WO 8907613 A1 US 5238839 A	17-09-1991 24-09-1992 06-09-1989 08-10-1990 09-01-1991 06-06-1991 24-08-1989 24-08-1993
WO 8902461	A	23-03-1989	DE 3731874 A1 AT 91303 T WO 8902461 A1 EP 0393039 A1 JP 3500241 T	30-03-1989 15-07-1993 23-03-1989 24-10-1990 24-01-1991